

CURRICULUM VITAE

JAY N. COHN, M.D.
USA

PROFESSIONAL ADDRESS

University of Minnesota Medical School
 Mayo Mail Code 508
 420 Delaware Street, S.E.
 Minneapolis, MN 55455
 (612) 625-5646

IDENTIFYING INFORMATION**Education**

Degree	Institution	Date Degree Granted
B.S.	Union College, Schenectady, NY	1952
M.D.	Cornell University Medical College	1956

Post-Graduate Training

Intern (Medicine), Beth Israel Hospital, Boston, Massachusetts, 1956-57
 Assistant Resident in Medicine, Beth Israel Hospital, Boston, Massachusetts, 1957-58
 Research Fellow in Medicine (Cardiovascular Research), Georgetown University Medical Center, Washington, D.C., 1960-61
 Chief Resident in Medicine, Veterans Administration Hospital, Washington, D.C., 1961-62
 Clinical Investigator (Cardiovascular Research), Veterans Administration Hospital, Washington, D.C., 1962-65

Certifications, Licenses

Certification: American Board of Internal Medicine	1963
Licensure: Medical License Number 21740	1974-present
DEA Number AC6355122	1960-present

Academic Appointments

University of Minnesota Medical School, Twin Cities campus, Department of Medicine, Cardiovascular Division (1974-present)

Professor	1974-present
-----------	--------------

Georgetown University School of Medicine, Washington, D.C., Department of Medicine, Cardiovascular Division (1965-1974)

Professor	1972-1974
Associate Professor	1968-1972
Assistant Professor	1965-1968

Academic Administrative Appointments

University of Minnesota Medical School, Twin Cities campus, Department of Medicine, Cardiovascular Division (1974-present)

Head, Cardiovascular Division 1974-1996

Georgetown University School of Medicine, Washington, D.C., Department of Medicine, Cardiovascular Division (1965-1974)

Co-Director, Cardiovascular Division 1972-1974

Executive Committee, Department of Medicine 1972-1974

Veterans Administration Hospital, Washington, D.C. (1965-1974)

Chief, Hypertension and Clinical Dynamics 1965-1974

Chairman, Research and Education Committee

Clinical/Hospital Appointments

1999-present

Director, Rasmussen Center for Cardiovascular Disease Prevention

Department of Medicine, Cardiovascular Division

University of Minnesota Medical School

National/International Appointments and Offices Held

President, International Society of Cardiovascular Pharmacotherapy, 2008-2010

Scientific Advisory Committee, Victor Chang Cardiac Research Institute, Sydney, Australia, 1997-

President, International Society of Hypertension, 1996-1998

Scientific Awards Committee, American Society of Hypertension, 1996-

Subcommittee, National Bureau for Information on Coronary (NBIC) Heart Disease Risk, 1996

NIH, NHLBI Special Emphasis Panel on Heart Failure Research, 1996

President, Heart Failure Society of America, 1995-1998

President-Elect, International Society of Hypertension, 1995-1996

Chairman, Intersocietal Affairs Committee, American Society of Hypertension, 1995-

WHO & Council on Geriatric Cardiology, Task Force on Cardiac Rehabilitation Education, 1995-

National Institutes of Health, National Institute Aging Geriatrics Program, Cardiovascular Aging

Advisory Group Panel, 1995

Vice-President, International Society of Hypertension, 1994-1996

NHLBI Workshop on the Artificial Heart: Planning for Evolving Technologies, 1994

WHO & Council on Geriatric Cardiology, Task Force on Heart Failure Education, 1994-

Organizing Committee, ISH-2000 -- 18th Scientific Meetings of the International

Society of Hypertension, Year 2000 (Chicago, Illinois), 1994-2000

WHO Task Force on Hypertension Education, Steering Committee, 1994-

Chairman of the Congress, 5th International Symposium on Cardiovascular Pharmacotherapy,

Minneapolis, Minnesota - August 1993

Chairperson, NIH-NIA Ad Hoc Review Committee, Pathologic Effects of Impaired Myocardial

Function in Older Persons, 1993

Committee Chairman, NHLBI Task Force on Research in Heart Failure, 1992-1994

Councilor, Association of Professors of Cardiology, 1992-1994
Institute of Medicine, Committee to Evaluate Artificial Heart Program of NHLBI, 1991-92
Co-Chair, Council on Hypertension and Atherosclerosis Education, 1990-1994
NIH, National Heart, Lung, and Blood Institute Research Review Committee A, 1990-92
President, The American Society of Hypertension, 1990-92
NIH, National Heart, Lung, and Blood Institute Task Force on Hypertension, 1990-91
Steering Committee, Digitalis Trials, NIH 1988-
Parent Committee-NIH, Specialized Centers of Research (SCOR), 1988-90
President-Elect, The American Society of Hypertension, 1988-90
Council Member, Central Society for Clinical Research, 1987-89
Vice President for Councils, American Heart Association, 1982-84
Member, Congressional Commission on the Federal Drug Approval Process, 1981-82
Chairman, Cardiovascular Subsection, Central Society for Clinical Research, 1980-81
Chairman, American Heart Association Council on Circulation, 1980-81
Chairman, V.A. Cooperative Studies - Vasodilator-Heart Failure Trials (V-HeFT), 1980-
Board of Directors, American Heart Association, 1979-84
Chairman, American Heart Association Scientific Sessions Program Committee, 1979-82
Chairman, Long-Range Planning Committee, Council on Circulation, American Heart Association, 1979
Chairman, Program Committee, Council on Circulation, American Heart Association, 1977-79
Research, American Heart Association, 1976-78
Chairman, Publications Committee, High Blood Pressure Research Council, American Heart Association, 1976-78
Chairman, Cardiopulmonary Section, American Society for Clinical Pharmacology & Therapeutics, 1976-80
Food and Drug Administration Cardiovascular and Renal Advisory Committee:
Member 1977-81; Chairman November 1979 - September 1981
Member, Ad Hoc Committee for Long Range Planning, Council for High Blood Pressure Research, American Heart Association, 1976-78
Member, Annual Scientific Sessions Committee, Council on Circulation, American Heart Association, 1976-78
Member, Executive Committee, Council for High Blood Pressure Research, American Heart Association, 1976-78
Executive Committee, Council on Circulation, American Heart Association, 1975-86
Chairman, Nominating Committee, Circulation Council, American Heart Association, 1975
Chairman, V.A. Cooperative Study on Vasodilator Therapy of Acute Myocardial Infarction, 1974-81
Hypertension Task Force, National Institutes of Health, 1974-75
Vice President, American Society for Clinical Pharmacology and Therapeutics, 1973-74
Member, Program Committee, Council for High Blood Pressure Research, American Heart Association, 1972-74
Chairman, Program Committee, American Society for Clinical Pharmacology & Therapeutics, 1971-72
Cardiovascular Studies Merit Review Board, V.A. Central Office, 1970-75
Chairman, American Federation for Clinical Research (Eastern Section), 1969-70

Professional Societies

American College of Cardiology (Fellow)
American College of Physicians (Fellow)
American Federation for Clinical Research
American Heart Association (Fellow); Council on Circulation; Council on High Blood Pressure Research (Medical Advisory Board); Council on Basic Cardiovascular Sciences
American Heart Association, Minnesota Affiliate (Board of Directors, 1979-85)
American Physiological Society (Circulation Group)
American Society for Clinical Investigation
American Society for Clinical Pharmacology and Therapeutics
American Society of Hypertension
American Society for Pharmacology and Experimental Therapeutics
American Association for the Advancement of Science (Fellow)
Association of American Physicians
Association of University Cardiologists
Central Society for Clinical Research
Heart Failure Society of America
International Academy of Cardiovascular Sciences (Fellow)
International Society of Cardiovascular Pharmacotherapy
International Society of Hypertension

Honorary Lectureships

James L. Berk Visiting Professor, Duke Heart Center, Durham, NC, 2012
2nd Annual Harold Buchwald Memorial Lecture on Heart Health, Winnipeg, 2009
Visiting Professor in Cardiology, Emory University, Atlanta, Georgia, 2005
Rose Weiss Visiting Professor, Lahey Clinic, Boston, Massachusetts, 2005
11th J.K. Alexander Visiting Professor, Michael E. DeBakey VAMC, Houston, Texas, 2005
Madrid Arrhythmia and Myocardium 2005, Madrid, Spain, 2005
William Withering Memorial Lecture, Madrid Arrhythmia & Myocardium 2004, Spain
James T. Willerson Visiting Professor & Lecturer, University of Texas Medical Center, Houston, 2003
Don C. & George C. Sutton Memorial Lecture in Cardiology, Evanston Hospital, Illinois, 2002
Fernando Cruz Foundation Lecturer, Madrid, 2001
J. Gerard Mudd Lecturer, Saint Louis University, St. Louis, Missouri, 2001
Robert Tigerstedt Lecturer, Finnish Hypertension Society, Helsinki, 2001
Tisdale Visiting Professor, University of Vermont, Burlington, 2000
Kaufman Center for Heart Failure Award, Cleveland Clinic Foundation, 1999
Spoleto-scienza Workshop, Spoleto, Italy, 1998
Dennis Lecturer, Methodist Hospital, Houston, Texas, 1998
Simon Dack Visiting Professor, Mt. Sinai Medical Center, New York, 1997
John J. Sampson Lectureship, University of California-San Francisco, 1997
John McGuire Visiting Professor, University of Cincinnati, 1997
Frank Berkman Memorial Lecture, University of Ottawa Heart Institute, 1996
Katz Memorial Lecture, Michael Reese Medical Center, Chicago, IL, 1995
Lou Gillespie Memorial Lecture, Washington Hospital Center, Washington, D.C., 1994
Criscitiello Visiting Professor, New England Medical Center, Boston, 1994
Helen S. Perlman Lecturer, New York Cardiological Society, 1993

Visiting International Chair of the National Institute for Scientific Research,
University of Gent, Belgium, 1993
George Alexander Gibson Lecture, Royal College of Physicians of Edinburgh, 1993
Emanuel Kiosk Cardiology Lecture, Beth Israel Medical Center, Newark, NJ, 1993
Louis Sudler Lectureship in Cardiology, Rush-Presbyterian-St. Luke's Med Ctr, Chicago, 1992
Larry B. Ellis Memorial Lecture, Harvard Medical School, 1990
Roger W. Robinson Lecture on Cardiovascular Disease, Medical Center of Massachusetts, 1989
Kenneth Rosen Memorial Lecture, University of Illinois-Chicago, 1989
J.B. Johnson Memorial Lecture, Washington, D.C.
Henry Jackson Lecture, New England Cardiovascular Society
John Kent Lewis Memorial Lecture, Stanford University
Annual Koppanyi Lecture, Georgetown University
David Littman Memorial Lecture, Harvard Medical School
Karl Wiggers Lecture, Western Reserve Medical School
Sujint Shay Memorial Lecture, Methodist Hospital, Peoria, Illinois
William Harvey Award Lecture, American Society of Hypertension
Chapman Lecture, Baylor University
John Herr Musser Lecture, Tulane University Medical School
G.D. Searle Lecture, Endocrine Society

Invited Lectures – Faculty

2015-

Abington Hospital Grand Rounds, Abington, PA
US-India Healthcare Summit 2015
Mini Medical School, University of Minnesota, Minneapolis, MN
Sarasota Memorial Hospital Symposium, Sarasota, FL

2014-

Bayfront Health Medical Center Grand Rounds, St. Petersburg, FL
Holy Cross Hospital Grand Rounds, Chicago, IL
Good Samaritan Medical Center Grand Rounds, Brockton, MA
Sarasota Memorial Hospital Grand Rounds, Sarasota, FL
American College of Cardiology Annual Scientific Meeting, Washington, DC
CVIS Symposium, Austria, Hungary
18th Annual Heart Failure Society of America Annual Meeting, Las Vegas, NV
American Heart Association Scientific Sessions, Chicago, IL
Grand Rounds, University of Minnesota, Minneapolis, MN

2013-

Association of University Cardiologists Annual Meeting, St Petersburg, FL
American College of Cardiology Annual Scientific Meeting, San Francisco, CA
CVIS Symposium, Sweden, Russia, Poland, Germany
17th Annual Heart Failure Society of America Annual Meeting, Orlando, FL
American Heart Association Scientific Sessions, Dallas, TX

2012-

Grand Rounds, Montefiore Medical Center, Bronx, NY, 2012

9th Annual Cardiology Fellow Symposium, Heart Failure Society of America, Aventura, FL
Sarasota Memorial Hospital Grand Rounds, Sarasota, FL
HFA of the ESC Heart Failure Clinical Trialists Workshop, Nice, France
Albert Einstein School of Medicine Grand Rounds, New York, NY
American College of Cardiology 61st Annual Scientific Session, Chicago, IL
Blumenthal Lecture, University of Minnesota, Minneapolis, MN
James L. Berk Visiting Professor, Duke University, Durham, NC
17th International Congress on Cardiovascular Pharmacotherapy, Bucharest, Romania
CVIS Symposium, England
Franz Halberg Lecture, University of Minnesota, Minneapolis, MN
60th Annual Scientific Meeting, Cardiac Society of Australia and New Zealand, Brisbane, Australia
16th Annual Heart Failure Society of America Annual Meeting, Seattle, WA
Chinese Heart Failure Society Annual Meeting, Beijing, China
VA Grand Rounds, VA Medical Center, Minneapolis, MN
Bache Lecture, University of Minnesota, Minneapolis, MN
Advanced Heart Failure Symposium, University of Minnesota, Minneapolis, MN
Frontiers in Global Health Research Symposium, Minneapolis, MN
American Heart Association Scientific Sessions, Los Angeles, CA
Medicinal Agents I Lecture, University of Minnesota, Minneapolis, MN
Frontiers in Biomedical Research, University of Minnesota, Minneapolis, MN

2011-

8th Annual Cardiology Fellow Symposium, Heart Failure Society of America, Aventura, FL
Interamerican Congress of Cardiology, Cartagena, Colombia
American College of Cardiology 60th Annual Scientific Session, New Orleans, LA
26th Annual Scientific Meeting, American Society of Hypertension, New York, NY
Cardiovascular Retreat, University of Minnesota, Minneapolis, MN
Grand Rounds, University of Minnesota, Minneapolis, MN
Cardiology Pathophysiology Small Group Lecture, University of Minnesota Minneapolis, MN
Dept. of Medicine Grand Rounds, University of Minnesota, Minneapolis, MN
15th Annual Heart Failure Society of America Annual Meeting, Boston, MA
Core Conference, University of Minnesota, Minneapolis, MN
Great Wall International Congress of Cardiology, Beijing, China
American Heart Association Scientific Sessions, Orlando, FL
16th International Congress on Cardiovascular Pharmacotherapy, Santiago, Chile

2010-

Association of University Cardiologists Annual Meeting, St. Petersburg, Florida
7th Annual Cardiology Fellow Symposium, Heart Failure Society of America, Aventura, Florida
ACC 59th Annual Scientific Session, Atlanta, GA
25th Annual Scientific Meeting, American Society of Hypertension, New York, NY
14th Annual Heart Failure Society of America Annual Meeting, San Diego, CA
23th Annual 19th International Cardiovascular Symposium, Southeast Asia
Scientific Sessions, American Heart Association, Chicago, IL
Global Cardiovascular Clinical Trialists Forum, Paris, France

2009-

Grand Rounds, Yale School of Medicine, New Haven, CT, 2009
Grand Rounds, Sarasota Memorial Hospital, Sarasota, Florida, 2009
6th Annual Cardiology Fellow Symposium, Heart Failure Society of America, Aventura, Florida
4th Annual Cardiovascular Symposium, Sarasota Memorial HealthCare, Sarasota, Florida
ACC 58th Annual Scientific Session, Orlando, Florida
24th Annual Scientific Meeting, American Society of Hypertension, San Francisco, California
17th Asian Pacific Congress of Cardiology, Kyoto, Japan
2nd Annual Meeting of the Minds, Montauk, New York
International Summit on Ischemic Heart Disease, Pisa, Italy
22th Annual 18th International Cardiovascular Symposium; Switzerland, Germany, France, Holland
13th Annual Heart Failure Society of America Annual Meeting, Boston, Massachusetts
American Society of Nuclear Cardiology Annual Meeting, Minneapolis, Minnesota
15th International Congress on Cardiovascular Pharmacotherapy, Beijing, China
Scientific Sessions, American Heart Association, Orlando, FL

2008-

Grand Rounds, Cleveland Clinic, Cleveland, Ohio, 2008
Grand Rounds, Washington Hospital Center, Washington, DC, 2008

2007-

Grand Rounds, Oregon and Health Sciences University, Portland, Oregon, 2007
Grand Rounds, Stanford University, Stanford, California, 2007

2005-

Grand Rounds, Abbott Northwestern, Minneapolis, Minnesota, 2005
Medicine Grand Rounds, Columbia University, New York, New York, 2005
Cardiology Grand Rounds, UCLA, Los Angeles, California, 2005
Vascular Biology Grand Rounds, Birmingham, Alabama, 2005
Cardiology/Medical Grand Rounds, George Washington University, Washington DC, 2005
Medical Grand Rounds Lecture at Bay Pines VA Medical Center, Bay Pines, Florida, 2005

Military service

Senior Assistant Surgeon and Surgeon, U.S. Public Health Service, USPHS Hospital,
Galveston, Texas, 1958-60

**HONORS AND AWARDS FOR RESEARCH WORK, TEACHING, PUBLIC ENGAGEMENT,
AND SERVICE**

University of Minnesota

Medical School Wall of Scholarship, 2015
Minnesota Cardiovascular Medal of Honor, University of Minnesota, 2012
University Innovations Award, University of Minnesota, 2012
Clinical Scholar Award, University of Minnesota, 2006
Academic Health Center Academy for Excellence in Health Research, University of Minnesota, 2003

External Sources

Heart and Stroke Hero Award, American Heart Association, 2012
 Distinguished Scientist Award, American Heart Association, 2010
 International Academy of Cardiovascular Sciences Life Achievement Award, 2009
 Alumni Association Award of Distinction, Weill Medical College of Cornell University, 2007
 Mastership, American College of Physicians, 2007
 Heart Failure Society of America Lifetime Achievement Award, 2006
 American College of Cardiology, Distinguished Scientist Award (Clinical Domain), 2005
 James B. Herrick Award, American Heart Association, 2003
 Lifetime Achievement in Research, Henry Ford Forum on Heart Failure, Detroit, Michigan, 2003
 Ignacio Chavez Medal of Honor, Interamerican Society of Heart Failure, Acapulco, 2003
 Arrigo Recordati International Prize for Scientific Research: Lifetime Achievement in Heart Failure, 2003
 International Scientist of the Year – 2003, International Biographical Centre, Cambridge, U.K.
 Council on High Blood Pressure Research (AHA) - Novartis Award in Hypertension Research, 2000
 Scientific Councils' Distinguished Achievement Award, American Heart Association, 1998
 Discovery Award, New Jersey Affiliate American Heart Association, 1998
 The Best Doctors in America: Central Region 1996-1997
 Who's Who in Medicine and Healthcare
 Medical Alley Award for Outstanding Contribution in Research and Development, 1993
 Listed in *Best Doctors in America*, 1992-1999, Woodward/White, Inc.
 The 400 Best Doctors in America, *Good Housekeeping*, 1992, 1996
 The 250 Top Doctors in Twin City Area, *Minneapolis-St Paul Magazine*, 1992
 Sir Thomas Lauder Brunton Award, 1988
 William S. Harvey Award, 1987
 Distinguished Service Award, American Heart Association, 1982
 Arthur S. Flemming Award, Federal Government Service, 1969
 Alpha Omega Alpha, Cornell University Medical College, 1955
 Annual Award, New York State Arthritis and Rheumatism Foundation, 1955
 New York State Medical School Scholarship (competitive)
 New York State College Scholarship (competitive)

RESEARCH AND SCHOLARSHIP

Publications

Original Research

1. Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, **Cohn JN**, Anker SD, Tavazzi L, Latini R on the behalf of GISSI-HF and Val-HeFT Investigators. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. *Eur J Heart Fail* 2015;17:424-433.
2. Ling HZ, Flint J, Damgaard M, Bonfils PK, Cheng AS, Aggarwal S, Velmurugan S, Mendonca M, Rashid M, Kang S, Papalia F, Weissert S, Coats CJ, Thomas M, Kuskowski

- M, **Cohn JN**, Woldman S, Anand IS, Okonko DO. Calculated plasma volume status and prognosis in chronic heart failure. *Eur J Heart Fail* 2015;17:35-43.
3. McNamara DM, Taylor AL, Tam SW, Worcel M, Yancy CW, Hanley-Yanez K, **Cohn JN**, Feldman AM. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. *JACC Heart Fail* 2014;2:551-557.
 4. Anand IS, Win S, Rector TS, **Cohn JN**, Taylor AL. Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: Results from the A-HeFT Trial. *Circ Heart Fail* 2014; 7:759-765.
 5. Anand IS, Rector TS, Kuskowski M, Snider J, **Cohn JN**. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. *Circ Heart Fail* 2014;7:418-426.
 6. Lesogor A, **Cohn JN**, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. *Eur J Heart Failure* 2013;15:1236-1244.
 7. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, **Cohn JN**. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. *Eur J Heart Fail* 2013;15:511-518.
 8. Saul SM, Duprez DA, Zhong W, Grandits GA, **Cohn JN**. Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: The DETECT study. *J Human Hypertension* 2013;27:362-367.
 9. Miedema MD, **Cohn JN**, Garberich RF, Knickelbine T, Graham KJ, Henry TD. Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. *Am Heart J* 2012;164:259-267.
 10. Taylor AL, Sabolinski ML, Tam SW, Ziesche S, Ghali JK, Archambault WT, Worcel M, **Cohn JN** for the A-HeFT Investigators. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American Heart Failure Trial. *J Card Failure* 2012;18(8):600-606.
 11. Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, **Cohn JN**, Latini R. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: Data from 2 large randomized clinical trials. *Circulation* 2012;125:280-288.
 12. Duprez DA, Florea N, Zhong W, Grandits GA, Hawthorne CK, Hoke L, **Cohn JN**. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. *J Amer Soc Hypertens* 2011;5:401-409.

13. Mitchell JE, Tam SW, Trivedi K, Taylor AL, O'Neal W, **Cohn JN**, Worcel M. Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT). *Am Heart J* 2011;162:154-159.
14. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan and losartan on cancers in 15 trials enrolling 138,769 individuals. *J Hypertens* 2011;24:623-35.
15. Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, **Cohn JN** on behalf of the Val-HeFT Investigators. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: Data from the Valsartan Heart Failure Trial (Val-HeFT). *J Card Fail* 2010;16:964-970.
16. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, **Cohn JN**; Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). *Congest Heart Fail* 2010; 16:191-95.
17. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, **Cohn JN**, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. *Circulation* 2010; 122:1387-95.
18. Carson P, Tam SW, Ghali JK, Archambault WT, Taylor A, **Cohn JN**, Braman VM, Worcel M, Anand IS. Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. *J Card Fail* 2009;15:835-842.
19. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, **Cohn JN**. Proteinuria, chronic kidney disease and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. *Circulation* 2009;120:1577-1584.
20. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, Ofili E, Yancy C, Feldman AM, Ghali JK, Taylor AL, **Cohn JN**, Worcel M. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. *J Card Fail* 2009;15(3):191-198.
21. **Cohn JN**, Wilson DJ, Neutel J, Houston M, Weinberger MH, Grimm Jr R, Smith DHG, Sun W. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. *Am J Hypertens* 2009;22(2):137-144.
22. Ghali JK, Tam SW, Sabolinski ML, Taylor AL, Lindenfeld J, **Cohn JN**, Worcel M. Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. *J Card Fail* 2008;14:718-723.

23. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, **Cohn JN** for the Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). *J Am Coll Cardiol* 2009;52:997-1003.
24. Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, **Cohn JN**. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. *Circulation* 2008; 1:34-42.
25. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, **Cohn JN**, Tognoni G, Latini R for the Valsartan Heart Failure Trial Investigators. Clinical, neurohormonal and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. *J Card Fail* 2007;13(10):797-804.
26. Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, **Cohn JN** for the A-HeFT Investigators. Effects of ACE inhibitors or β -blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. *Am J Cardiovasc Drugs* 2007;7(5):373-380.
27. Tam SW, Worcel M, Sabolinski ML, Packer M, **Cohn JN**. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine. The V-HeFT Paradox. *Clin Pharmacokinet* 2007;46:885-895.
28. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, **Cohn JN** for the Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. *Circulation* 2007;116:1242-1249.
29. Duprez DA, Florea ND, Jones K, **Cohn JN**. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: The DETECTIV Pilot Study. *J Am Coll Cardiol* 2007;50:835-839.
30. **Cohn JN**, Tam W, Anand IS, Taylor AL, Sabolinski ML, Worcel M for the A-HeFT Investigators. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: Results from A-HeFT. *J Card Failure* 2007;13(5):331-339.
31. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, **Cohn JN** for the African-American Heart Failure Trial Investigators. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: Consistency across subgroups in the African-American Heart Failure Trial. *Circulation* 2007;115(13):1747-53.

32. Gilani M, Kaiser DR, Bratteli CW, Alinder C, Rajala S, Bank AJ, **Cohn JN**. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. *J Amer Soc Hypertens* 2007;1(1):45-55.
33. Cicoira M, Maggioni AP, Latini R, Barlera S, Carretta E, Janosi A, Soler J, Anand I, **Cohn JN** on behalf of Val-HeFT Investigators. Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. *Eur J Heart Fail* 2007;9(4):397-402.
34. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, **Cohn JN**. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. *J Am Coll Cardiol* 2007;49(1):32-39.
35. Taylor AL, Lindenfeld J, Ziesche S, Walsh N, Mitchell JE, Adams K, Tam SW, Ofili E, Sabolinski ML, Worcel M, **Cohn JN** for the A-HeFT Investigators. Outcomes by gender in the African-American Heart Failure Trial. *J Am Coll Cardiol* 2006;48:2263-2267.
36. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, **Cohn JN**, Feldman AM, Worcel M. Aldosterone synthase promoter polymorphism predicts outcome in African-Americans with heart failure: Results from the A-HeFT Trial. *J Am Coll Cardiol* 2006;48(6):1277-82.
37. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, **Cohn JN** for the Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. *Clin Chem* 2006;52(8):1528-38.
38. Masson S, Latini R, Anand IS, Barlera S, Judd D, Salio M, Perticone F, Perini G, Tognoni G, **Cohn JN** on behalf of the Val-HeFT Investigators. The prognostic value of Big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan in Heart Failure Trial (Val-HeFT). *J Card Failure* 2006;12(5):375-380.
39. **Cohn JN**, Carson PE, O'Connor C, Opasich C, Piña IL, Scherillo M, Sinagra G, Warner-Stevenson L, Tristani FE, Volpi A. Prognosis and mechanism of death in treated heart failure: Data from the placebo arm of Val-HeFT. *Congestive Heart Failure* 2006;12(3):127-131.
40. Rector TS, Anand IS, **Cohn JN**. Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life. *J Card Failure* 2006;12(2):87-92.
41. Wong M, Staszewsky L, Carretta E, Barlera S, Latini R, Chiang YT, Glazer RD, **Cohn JN**. Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care-data from Val-HeFT. *Eur J Heart Failure* 2006;8:502-508.
42. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, Vago T, Maggioni AP, Anand IS, Tan LB, Tognoni G, **Cohn JN** for the Val-HeFT Investigators. Incremental

- prognostic value of changes in B-type natriuretic peptide in heart failure. *Am J Med* 2006;119(1):70.
43. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, Tavazzi L, Latini R, **Cohn JN**. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. *Journal of Cardiac Failure* 2005;11(2):91-98.
 44. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, **Cohn JN**. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. *Circulation* 2005;112(8):1121-7.
 45. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, **Cohn JN**; Val-HeFT Investigators. C-reactive protein in heart failure: prognostic value and the effect of valsartan. *Circulation* 2005;112(10):1428-34.
 46. Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, **Cohn JN**, Tavazzi L. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. *J Card Fail* 2005, 11(4):253-9.
 47. Duprez DA, Somasundaram PE, Sigurdsson G, Hoke L, Florea N, **Cohn JN**. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. *J Hum Hypertens* 2005 Jul;19(7):515-9.
 48. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, **Cohn JN**. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 2005;149(3):548-57.
 49. Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, **Cohn JN**. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 2004;148:951-957.
 50. Sarabandi T, **Cohn J**, Cornelissen G, Halberg F, Katinas G, Holte J, Schwartzkopff O, Otsuka K. No baseline for blood pressure in ordinary life: another case of transient chromosome alterations. *Biomedicine & Pharmacotherapy* 2004;58:S107-S110.
 51. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, **Cohn JN**: Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. *Eur J Heart Fail* 2004:937-945.
 52. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, **Cohn JN**, for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004;351:2049-2057.

53. Anand I, McMurray J, **Cohn JN**, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF, EARTH investigators: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004;364:347-354.
54. Duprez DA, Kaiser DR, Whitwam W, Finkelstein S, Belalcazar A, Patterson R, Glasser S, **Cohn JN**. Determinants of radial artery pulse wave analysis in asymptomatic individuals. *Am J Hypertens* 2004;17:647-653.
55. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, Hester A, Anand I, **Cohn JN**. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. *J Am Coll Cardiol* 2004;43:2022-2027.
56. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, **Cohn JN**. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. *Circulation* 2004;109:984-989.
57. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, **Cohn JN**, for the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. *Eur Heart J* 2004;25:292-299.
58. **Cohn JN**, Julius S, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Guo W, Lagast H. Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. *Am J Hypertens* 2004; 17:134-138.
59. Julius S, **Cohn JN**, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Lagast H. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. *J Clin Hypertension* 2004;6:10-17.
60. **Cohn JN**. Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure. *J Renin Angiotensin Aldosterone Syst* 2003;4:137-139.
61. **Cohn JN**, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail* 2003; 5:659-667.
62. **Cohn JN**, Hoke L, Whitwam W, Sommers PA, Taylor AL, Duprez D, Roessler R, Florea N. Screening for early detection of cardiovascular disease in asymptomatic individuals. *Am Heart J* 2003;146:679-685.
63. **Cohn JN**, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, for the Val-HeFT Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. *Circulation* 2003;108:1306-1309.

64. Carson P, Tognoni G, **Cohn JN**. Effect of valsartan on hospitalization: results from Val-HeFT. *J Cardiac Fail* 2003;9:164-174.
65. Anker SD, Negassa A, Coats AJ, Poole-Wilson PA, **Cohn JN**, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. *Lancet* 2003;29: 1007-1083.
66. Grey E, Bratteli C, Glasser SP, Alinder C, Finkelstein SM, Lindgren BR, **Cohn JN**. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. *Am J Hypertens* 2003;16:265-269.
67. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, **Cohn JN**. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). *Circulation* 2003;107:1278-83.
68. Taylor AL, **Cohn JN**, Worcel M, Franciosa JA. The African-American Heart Failure Trial: background, rationale and significance. *J Natl Med Assoc* 2002;94:762-769.
69. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, **Cohn JN**. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). *Circulation* 2002; 106:2454-2458.
70. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, **Cohn JN**. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. *J Am Coll Cardiol* 2002;16:1414-1421.
71. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, **Cohn JN**. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. *J Am Coll Cardiol* 2002;4:970-975.
72. Franciosa JA, Taylor AL, **Cohn JN**, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M, for the A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): Rationale, design, and methodology. *J Cardiac Fail* 2002;8:128-135.
73. Swedberg K, Bristow MR, **Cohn JN**, Dargie H, Straub M, Wiltse C, Wright TJ. Moxonidine safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. *Circulation* 2002;105:1797-1803.
74. Duprez DA, De Buyzere ML, De Bruyne L, Clement DL, **Cohn JN**. Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD). *Vascular Med*, 2001;6:211-214.

75. **Cohn JN**, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345:1667-75.
76. Beltran A, McVeigh G, Morgan D, Glasser SP, Neutel JM, Weber M, Finkelstein SM, **Cohn JN**. Arterial compliance abnormalities in isolated systolic hypertension. *Am J Hypertens* 2001;14:1007-11.
77. **Cohn JN**. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. *Am J Hypertens* 2001;14:258S-63S.
78. Duprez DA, De Buyzere ML, De Backer TL, Van De Veire N, Clement DL, **Cohn JN**. Relationship between arterial elasticity indices and carotid artery intima-media thickness. *Am J Hypertens* 2000;13:1226-1232.
79. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, **Cohn JN**, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. *J Am Coll Cardiol* 2001;37:1692-1699.
80. **Cohn JN**. New approaches to screening for vascular and cardiac risk. *Am J Hypertens*; 2001;14:6-2.
81. Duprez DA, De Buyzere ML, Van den Noortgate N, Simoons J, Achten E, Clement DK, Afschrift M, **Cohn JN**. Relationship between periventricular or deep white matter lesions and arterial elasticity indices in very old people. *Age & Ageing* 2001;30:325-330.
82. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, **Cohn JN**, Lukas MA, Young ST, Packer M, for the U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *N Engl J Med* 2001;345:1358-1365.
83. Exner DV, Dries DL, Domanski MJ, **Cohn JN**. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. *N Engl J Med* 2001;344:1351-1357.
84. Arnett DK, Glasser SP, McVeigh G, Prineas R, Finklestein S, Donahue R, **Cohn JN**, Sinaiko A. Blood pressure and arterial compliance in young adults: The Minnesota Children's Blood Pressure Study. *Am J Hypertens* 2001;14:200-205.
85. **Cohn JN**, Tognoni G, Glazer R, Spormann D on behalf of the Val-HeFT Investigators. Baseline demographics of the Valsartan Heart Failure Trial. *Euro J Heart Failure* 2000;2:439-446.
86. Reis SE, Holubkov R, Young JB, White BG, **Cohn JN**, Feldman AM. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. *J Am Coll Cardiol* 2000;36:529-533.

87. Smith RF, Germanson T, Judd D, Wong M, Ziesche S, Anand IS, Taylor WR, **Cohn JN**, for the V-HeFT III Investigators. Plasma norepinephrine and atrial natriuretic peptide in heart failure: Influence of felodipine in the Third Vasodilator Heart Failure Trial. *J Cardiac Fail*, 2000;6:97-107. Reis SE, Holubkov R, Young JB, White BG, Cohn JN, Feldman AM: Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. *J Am Coll Cardiol* 2000;36:529-533.
88. Wong M, Germanson T, Taylor WR, Cohen IS, Perry G, Baruch L, Deedwania P, Lopez B, **Cohn JN**. Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III. Echocardiographic substudy of multicenter reproducibility and detecting functional change. *J Cardiac Fail* 2000;6:19-28.
89. Black HR, Kuller LH, O'Rourke MF, Weber MA, Alderman MH, Benetos A, Burnett J, **Cohn JN**, Franklin SS, Mancia G, Safar M, Zanchetti A. The first Report of the Systolic and Pulse Pressure (SYPP) Working Group. *J Hypertension* 1999; 17(Suppl 5):S3-14.
90. Carson P, Ziesche S, Johnson G, **Cohn JN**, for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: Analysis of the Vasodilator-Heart Failure Trials. *J Cardiac Fail* 1999;5:178-187.
91. **Cohn JN**, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and Design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. *J Cardiac Fail* 1999;5:155-160.
92. McVeigh GE, Bratteli CW, Morgan DJ, Alinder CM, Glasser SP, Finkelstein SM, **Cohn JN**. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis. *Hypertension* 1999;33:1392-1398 .
93. Tian B, Carlyle WC, Weigold WG, McDonald KM, Judd DL, Toher CA, Homans DC, **Cohn JN**. Localization of changes in β -actin expression in remodeled canine myocardium. *J Mol Cell Cardiol* 1999;31:751-760.
94. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, **Cohn JN**, for the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. *Circulation* 1999;99:2658-2664.
95. **Cohn JN**, Goldstein S, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew, III, F, DeMets DL, White BG, for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. *N Engl J Med* 1998;339:1810-1816.

96. López-Beltrán EA, Blackshear PL, Finkelstein SM, **Cohn JN**. Non-invasive studies of peripheral vascular compliance using a non-occluding photoplethysmographic method. *Med Biol Eng Comput* 1998;36:748-753.
97. Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AK, Morgan DJ, **Cohn JN**:. The importance of arterial compliance in cardiovascular drug therapy. *J Clin Pharmacology* 1998;38:202-212.
98. McDonald KM, D'Aloia A, Parrish T, Mock J, Hauer K, Stillman AE, **Cohn JN**: Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition. *J Cardiac Fail* 1998;4:203-212.
99. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, **Cohn JN**. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. *Euro Heart J* 1998;19:1371-1376.
100. McDonald KM, Chu C, Francis GS, Carlyle W, Judd DL, Hauer K, Hartman M, **Cohn JN**. Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction. *J Mol Cell Cardiol* 1997;29:3203-3210.
101. **Cohn JN**, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. *J Cardiac Fail*, 1997;3:173-179.
102. **Cohn JN**, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L, for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. *Circulation* 1997;96:856-863.
103. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997;336:525-533.
104. McVeigh GE, Morgan DJ, Finkelstein SM, Lemay LA, **Cohn JN**. Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis. *Am J Med* 1997;102:227-231.
105. Colucci WS, Packer M, Bristow MR, Gilbert EM, **Cohn JN**, Fowler MB, Krueger SK, Hersberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. *Circulation* 1996;94:2800-2806.
106. McVeigh GE, LeMay L, Morgan D, **Cohn JN**. Effects of long-term cigarette smoking on endothelium-dependent responses in humans. *Am J Cardiol* 1996;78: 668-672.

107. **Cohn JN**. Is there a role for endothelin in the natural history of heart failure? Editorial. *Circulation* 1996;94:604-606.
108. The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. *Controlled Clin Trials* 1996;17:77-97.
109. Boden WE, Ziesche S, Carson PE, Conrad CH, Syat D, **Cohn JN**, for the V-HeFT III Investigators. Rationale and design of the third Vasodilator-Heart Failure Trial (V-HeFT III): *felodipine* as adjunctive therapy to *enalapril* and loop diuretics with or without *digoxin* in chronic congestive heart failure. *Am J Cardiol* 1996, 77: 1078-1082.
110. Packer M, Bristow MR, **Cohn JN**, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996;334:1349-1355.
111. Carson P, Johnson G, Fletcher R, **Cohn J**, for the V-HeFT Cooperative Study Group. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%: baseline characteristics, prognosis and response to therapy in Vasodilator in Heart Failure Trials (V-HeFT). *J Am Coll Cardiol* 1996;27:642-649.
112. Carlyle WC, Toher CA, Vandervelde JR, McDonald KM, Homans DC, **Cohn JN**: Changes in β -actin mRNA expression in remodeling canine myocardium. *J Molecular Cellular Cardiol* 1996;28:53-63.
113. **Cohn JN**, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, Mock J: Non-invasive pulse wave analysis for the detection of arterial vascular disease. *Hypertension* 1995; 26:503-508.
114. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, **Cohn JN**. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. *Circulation* 1995;91:2043-2048.
115. Ziesche S, Rector TS, **Cohn JN**. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. *J Cardiac Fail* 1995;1:127-132.
116. McDonald KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parish T, Stillman A, **Cohn JN**. Relative effects of α_1 adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. *Circulation* 1994;90:3034-3046.
117. McDonald KM, Rector T, Carlyle PF, Francis GS, **Cohn JN**. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. *JACC* 1994;24:1762-1768.

118. McVeigh GE, Brennan GM, Finkelstein SM, Johnston GD, Hayes JR, **Cohn JN**: Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. *Arteriosclerosis & Thrombosis* 1994;14:1425-1429.
119. Connelly TP, Francis GS, Williams KJ, Beltran AM, **Cohn JN**. Interaction of intravenous atrial natriuretic factor with furosemide in patients with heart failure. *Am Heart J* 1994;127:392-399.
120. McDonald KM, Yoshiyama M, Francis GS, Ugurbil K, **Cohn JN**, Zhang J: Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. *J Am Col Cardiol* 1994;23:786-793.
121. Haidet GC, **Cohn JN**. Pathophysiological changes in elderly patients with chronic heart failure. *Cardiol in the Elderly* 1994;2:71-82.
122. McVeigh G, Brennan G, Hayes R, **Cohn J**, Finkelstein S, Johnston D. Vascular abnormalities in non-insulin-dependent diabetes mellitus identified by arterial waveform analysis. *Am Jnl Med* 1993, 95:424-430.
123. Patterson R, Wang L, McVeigh G, Burns R, **Cohn JN**. Impedance cardiography: The failure of sternal electrodes to predict changes in stroke volume. *Biol Psych* 1993; 36:33-41.
124. Hughes CV, Wong M, Johnson G, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Influence of age on mechanisms and prognosis of heart failure. *Circulation* 1993;87(Suppl VI):VI-111-117.
125. Carson P, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: The V-HeFT studies. *Circulation* 1993; 87(Suppl VI):VI-102-110.
126. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, **Cohn JN**. Incidence of thromboembolic events in congestive heart failure. *Circulation* 1993;87(Suppl VI):VI-94-101.
127. Smith RF, Johnson G, Ziesche S, Bhat G, Blankenship K, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Functional capacity in heart failure: comparison of methods for assessment and their relation to other indexes of heart failure. *Circulation* 1993;87(Suppl VI):VI-88-93.
128. Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. The effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. *Circulation* 1993;87(Suppl VI):VI-78-87.
129. Rector TS, Johnson G, Dunkman WB, Daniels G, Farrell L, Henrick A, Smith B, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Evaluation by patients with heart failure of the

effects of enalapril compared to hydralazine plus isosorbide dinitrate on quality of life. *Circulation* 1993;87(Suppl VI):VI-71-77.

130. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans Affairs Cooperative Studies V-HeFT I and II. *Circulation* 1993;87(Suppl VI):VI-65-70.
131. Ziesche S, Cobb FR, **Cohn JN**, Johnson G, Tristani F, for the V-HeFT VA Cooperative Studies Group. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure: Results from V-HeFT I and V-HeFT II. *Circulation* 1993;87(Suppl VI):VI-56-64.
132. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. *Circulation* 1993; 87(Suppl VI):VI-49-55.
133. Francis GS, **Cohn JN**, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. *Circulation* 1993;87(Suppl VI):VI-40-48.
134. Johnson G, Carson P, Francis GS, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). *Circulation* 1993;87(Suppl VI): VI-32-39.
135. Goldman S, Johnson G, **Cohn JN**, Cintron G, Smith R, Francis G, for the V-HeFT VA Cooperative Studies Group. Mechanism of death in heart failure: The Vasolidator-Heart Failure Trials. *Circulation* 1993;87 (Suppl VI):VI-24-31.
136. Cintron G, Johnson G, Francis G, Cobb F, **Cohn JN**, for the V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. *Circulation* 1993;87(Suppl VI):VI-17-23.
137. **Cohn JN**, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R, for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. *Circulation* 1993;87(Suppl VI):VI-5-16.
138. Rector TS, Kubo SH, **Cohn JN**. Validity of the Minnesota Living with Heart Failure Questionnaire as a measure of therapeutic response: Effects of enalapril and placebo. *Am J Cardiol* 1993;71:1106-1107.
139. McDonald KM, Francis GS, Matthews JH, Hunter D, **Cohn JN**. Long-term oralnitrate therapy prevents chronic ventricular remodeling in the dog. *J Am Coll Cardiol* 1993;21: 514-522.

140. Rector TS, **Cohn JN**, with the Pimobendan Multicenter Research Group: Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. *Am Heart J* 1992;124:1017-1025.
141. **Cohn JN**, Finkelstein SM. Abnormalities of vascular compliance in hypertension, aging and heart failure. *J Hypertension* 1992;10:S61-S64.
142. Finkelstein SM and **Cohn JN**. First- and third-order models for determining arterial compliance. *J Hypertension* 1992;10:S11-S14.
143. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992;327:685-691.
144. Katz SD, Kubo SH, Jessup M, Brozena S, Troha JM, Wahl J, **Cohn JN**, Sonnenblick EH, LeJemtel TH. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. *Am Heart J* 1992;123:95-103.
145. McDonald KM, Parrish T, Wennberg P, Stillman AE, Francis GS, **Cohn JN**, Hunter D. Rapid, accurate and simultaneous non-invasive assessment of right and left ventricular mass using snap shot gradient echo magnetic resonance imaging. *J Am Coll Cardiol* 1992;19:1601-1607.
146. Kubo SH, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, Brozena S, Brodsky M, Kirlin P, Shanes J, Konstam M, Gradman A, Morledge J, Cinquegrani M, Singh S, LeJemtel T, Nicklas J, Troha J, **Cohn JN**, for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of a multicenter trial. *Circulation* 1992;83:942-949.
147. McDonald KM, Francis GS, Carlyle PF, Hauer K, Matthews J, Hunter DW, **Cohn JN**. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. *JACC* 1992;19:460-67.
148. Finkelstein SM, Burns DE, Chen K, McVeigh GE, **Cohn JN**. A comparison of invasive and non-invasive blood pressure measurements for determining arterial vascular compliance. *IEEE Engineer Med Biol Soc Proc* 1991;13:2073-2074.
149. **Cohn JN**, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991;325:303-310.

150. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991; 325:293-302.
151. McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W, Carlyle PF, Flack J, Grimm R, **Cohn JN**. Reduced vascular compliance as a marker for essential hypertension. *Am J Hypertension* 1991;4:245-251.
152. McDonald KM, Carlyle PF, Matthews J, Hauer K, Elbers T, Hunter D, **Cohn JN**. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. *Trans Assoc Amer Physicians* 1990;103:229-235.
153. Francis GS, Johnson TH, Boosalis P, Ziesche SM, Berg M, **Cohn JN**. Marked spontaneous improvement in ejection fraction in patients with congestive heart failure and a low ejection fraction. *Am J Med* 1990;89:303-307.
154. Finkelstein SM, McVeigh GE, Burns DE, Carlyle PF, **Cohn JN**. Arterial vascular compliance in heart failure. *IEEE Engineer Med Biol Soc Proc* 1990;12:548-549.
155. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD) - rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. *Am J Cardiol* 1990;66:315-322.
156. Fifer MA, Molina CR, Quiroz AC, Giles TD, Herrmann HC, DeScheeder IR, Clement DL, Kubo SH, Cody RJ, **Cohn JN**, Fowler MB. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. *Am J Cardiol* 1990;65:211-216.
157. McDonald KM, Sanchez de la Pena S, Cavallini M, Olivari MT, **Cohn JN**, Halberg F. Chronobiologic blood pressure and heart rate assessment of patients with heart transplants. In: *Chronobiology: Its Role in Clinical Medicine, General Biology, and Agriculture, Part B*. Wiley-Liss, Inc., 1990, 471-480.
158. Kubo SH, Rector TS, Heifetz SM, Sato H, **Cohn JN**. Atrial natriuretic factor attenuates sympathetic reflexes during lower body negative pressure in normal men. *J Cardiovasc Pharmacol* 1990;16:881-889.
159. Carlyle PF, **Cohn JN**. Systemic and regional hemodynamic effects of alpha adrenoceptor blockade in chronic left ventricular dysfunction in the conscious dog. *Am Heart J* 1990;120:619-624.
160. Carson P, Carlyle PF, Rector TS, **Cohn JN**. Cardiovascular and neurohormonal effects of atrial natriuretic peptide in conscious dogs with and without chronic left ventricular dysfunction. *J Cardiovasc Pharmacol* 1990; 16: 305-311.
161. **Cohn JN**, Johnson G. Heart failure with normal ejection fraction: The V-HeFT Study. *Circulation* 1990; 81 (Suppl III): III-48 - III-53.

162. Finkelstein SM, McVeigh GE, Burns ED, McDonald KM, Carlyle PF, **Cohn JN**. Reproducibility of arterial vascular compliance measurements. *IEEE Engineer Med Biol Soc Proc* 1989; 11: 116-117.
163. Kubo SH, Rector TS, Heifetz SM, **Cohn JN**. Alpha 2-receptor-mediated vasoconstriction in patients with congestive heart failure. *Circulation* 1989;80: 1660-1667.
164. Goldsmith SR, Francis GS, **Cohn JN**. Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. *Am J Cardiol* 1989; 64: 1382-1385.
165. Goldenberg IF, Olivari MT, Levine TB, **Cohn JN**. Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy. *Am J Cardiol* 1989; 63: 843-846.
166. Francis GS, Rector TS, **Cohn JN**. Sequential neurohumoral measurements in patients with congestive heart failure. *Am Heart J* 1988; 63: 843-846.
167. **Cohn JN** and the Veterans Administration Cooperative Study Group. Effect of vasodilator therapy on mortality in chronic congestive heart failure. *Eur Heart J* 1988; 9: 171-173.
168. Kubo SH, Rector TS, Strobeck JE, **Cohn JN**. OPC-8212 in the treatment of congestive heart failure: Results of a pilot study. *Cardiovascular Drugs and Therapy* 1988;2:653-660.
169. **Cohn JN**, Rector TS. Prognosis of congestive heart failure and predictors of mortality. *Am J Cardiol* 1988; 62: 25A-30A.
170. Finkelstein SM, Feske W, Mock JE, Carlyle P, Rector T, Kubo S, **Cohn JN**. Vascular compliance in hypertension. *IEEE Engineer Med Biol Society 10th Annual Int'l Conf Proc* 1988; pp. 241-242.
171. Feske W, Finkelstein SM, Francis G, **Cohn JN**. Vascular compliance after nitroprusside in hypertension. *IEEE Proceedings 14th Annual N.E. Bioengineer Symp* 1988, pp. 277-280.
172. Finkelstein SM, Collins VR, **Cohn JN**. Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis. *Hypertension* 1988; 12: 380-387.
173. Feske W, Finkelstein SM, Francis G, **Cohn JN**. Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis. *Instrument Soc of Amer Biomedical Sciences Instrumentation* 1988; 24: 161-165.
174. Mock JE, Finkelstein SM, Eaton J, Hatfield G, **Cohn JN**. Vasoconstrictor drug effects on vascular compliance by pulse contour analysis. *IEEE Engineer Med Biol Society Proceedings* 1987; 9: 878-880.

175. Mock JE, Finkelstein SM **Cohn JN**, Eaton J, Hatfield G Vascular compliance changes in hypertensive dogs after nitroprusside infusion as measured by pulse contour analysis. *Instrument Soc of Amer Biomedical Sciences Instrumentation* 1987;23:77-82.
176. Tristani FE, Hughes VC, Archibald DG, Sheldahl LM, **Cohn JN**. Safety of graded symptom-limited exercise testing in patients with congestive heart failure. *Circulation* 1987; 76(Suppl VI): VI54-VI58.
177. Chen DG, Carlyle P, Carlyle W, Eekhoff P, **Cohn JN**. Adrenergic mechanism of femoral arterial constriction during carotid occlusion in dogs. *Acta Pharm Sinica* 1987; 8: 438-442.
178. Olivari MT, Levine TB, Ring WS, Simon A, **Cohn JN**. Normalization of sympathetic nervous system function after orthotopic cardiac transplant in man. *Circulation* 1987; 76: V62-V64.
179. Rector TS, Kubo SK, **Cohn JN**. Patient's self-assessment of their congestive heart failure. Part 2. Content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. *Heart Failure* 1987; 3: 198-209.
180. Rector TS, Francis GS, **Cohn JN**. Patient's self-assessment of their congestive heart failure. Part 1. Patient perceived dysfunction and its poor correlation with maximal exercise tests. *Heart Failure* 1987; 3: 192-196.
181. Petein M, Heppner B, Bache RJ, **Cohn JN**: Pierpont GL. Hemodynamic and regional blood flow response to Piroximone (MDL 19, 205) in dogs with congestive heart failure: A comparison with Dobutamine. *J Cardiovasc Pharmacol and Exp Ther* 1987; 241: 956-960.
182. Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Ring WS, Goldenberg IF, Reynolds S, **Cohn JN**. Heterogeneous myocardial catecholamine concentrations in patients with congestive heart failure. *Am J Cardiol* 1987; 60: 316-321.
183. Rector TS, Olivari MT, Levine TB, Francis GS, **Cohn JN**. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. *Am Heart J* 1987; 114: 148-152.
184. Carson PE, Carlyle PF, **Cohn JN**. Cardiac and regional vascular effects of atrial natriuretic peptide in awake dogs with left ventricular dysfunction. *Trans Assoc Am Physicians XCIX*: 1987; pp. 34-38.
185. **Cohn JN**, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Veterans Administration Cooperative Study on vasodilator therapy of heart failure: Influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. *Circulation* 1987; 75: IV49-IV54.

186. Matangi MF, **Cohn JN**. Beneficial effects of atrioventricular synchrony in dogs with right coronary artery embolization, and complete heart block. *Can J Cardiol* 1987; 3: 144-147.
187. Archer SL, Chesler E, **Cohn JN**, Weir EK. ZK 36-374, a stable analog of prostacyclin, reverses acute hypoxic pulmonary hypertension in the dog. *J Am Coll Cardiol* 1986; 8: 1189-1194.
188. Levine TB, Olivari MT, **Cohn JN**. Effects of orthotopic heart transplantation on sympathetic control mechanisms in congestive heart failure. *Am J Cardiol* 1986; 58: 1035-1040.
189. Olivari MT, Levine TB, **Cohn JN**. Evidence for a direct renal stimulating effect of prostaglandin E₂ on renin release in patients with congestive heart failure. *Circulation* 1986; 74: 1203-1207.
190. Simon G, Wittig VJ, **Cohn JN**. Transdermal nitroglycerin as a step 3 antihypertensive drug. *Clin Pharmacol Ther* 1986; 40: 42-45.
191. Goldsmith SR, Francis GS, Cowley AW, Goldenberg IF, **Cohn JN**. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. *J Am Coll Cardiol* 1986;8:779-783.
192. Levine TB, Olivari MT, **Cohn JN**. Dissociation of the responses of the renin-angiotensin system and sympathetic nervous system to a vasodilator stimulus in congestive heart failure. *Int J Cardiol* 1986;12:165-173.
193. Olivari MT, Levine TB, **Cohn JN**. Acute hemodynamic and hormonal effects of central versus peripheral sympathetic inhibition in patients with congestive heart failure. *J Cardiovasc Pharmacol* 1986;8:973-977.
194. **Cohn JN**, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). *N Engl J Med* 1986;314:1547-52.
195. Petein M, Levine TB, **Cohn JN**. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure. *Circulation* 1986;73:230-236.
196. Goldsmith SR, Francis GS, **Cohn JN**. Effect of head-down tilt on basal plasma norepinephrine and renin activity in humans *J Appl Physiol* 1985;59:1068-1071.
197. Rector TS, **Cohn JN**. Quality of life and congestive heart failure: Implications for clinical care. *Quality of Life and Cardiovascular Care* 1985;1:262-266.
198. Sharkey SW, Shelley W, Carlyle PF, Rysavy J, **Cohn JN**. M-mode and two-dimensional echocardiographic analysis of the septum in experimental right ventricular infarction: Correlation with hemodynamic alterations. *Am Heart J* 1985; 110:1210-1218.

199. Rector TS, Carlyle PF, **Cohn JN**. Reduced atrial natriuretic factor after ligation of the left coronary artery in rats. *Am Heart J* 1985;110:1197-1199.
200. Goldsmith Sr, Francis GS, **Cohn JN**. Norepinephrine infusions in congestive heart failure. *Am J Cardiol* 1985;56:802-804.
201. Goldsmith SR, Cowley AW, Jr., Francis GS, **Cohn JN**. Reflex control of osmotically stimulated vasopressin in normal humans. *Am J Physiol* 1985; 248 (Regulatory Integrative Comp Physiol 17):R660-R663.
202. **Cohn JN**. Nitrates for congestive heart failure. In: A Symposium: Role of Nitrates in Congestive Heart Failure. *Am J Cardiol* 1985;56:1a-26a.
203. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, **Cohn JN**. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. *Ann Intern Med* 1985;103:1-6.
204. Pierpont GL, DeMaster E, Reynolds S, Pederson J, **Cohn JN**. Ventricular myocardial catecholamines in primates. *J Lab Clin Med* 1985;106:205-210.
205. Francis GS, Goldsmith SR, Ziesche S, Nakajima H, **Cohn JN**. Relative attenuation of sympathetic drive during exercise in patients with congestive heart failure. *J Am Coll Cardiol* 1985;5:832-839.
206. **Cohn JN**, Yellin AM. Learned precise cardiovascular control through graded central sympathetic stimulation. *Hypertension* 1984;2:77-79.
207. Olivari MT, Levine TB, **Cohn JN**. Acute hemodynamic effects of nitrendipine in chronic congestive heart failure. *J Cardiovasc Pharmacol* 1984;6:S1002-S1005.
208. Finkelstein SM, **Cohn JN**, Collins RV, Carlyle PF, Shelley W. Vascular hemodynamic impedance in congestive heart failure. *Am J Cardiol* 1985;55:423-427.
209. Petein M, Pierpont GL, Francis GS, **Cohn JN**, From AHL. In vivo interaction of AR-L 115BS (Vardax) with the adrenergic nervous system. *J Cardiovasc Pharmacol* 1984;6:1020-1026.
210. Gomes AS, Sinaiko AR, Tobian L, **Cohn JN**, Formanek AG, Roe DJ, Amplatz K: Renal vein renin sampling in essential hypertension using hydralazine and the tourniquet test. *Radiology* 1984;153:619-623.
211. Pierpont GL, Reynolds S, DeMaster EG, **Cohn JN**. Quantitative analysis of post-mortem changes in myocardial norepinephrine using HPLC with electrochemical detection. *J Lab Clin Med* 1984;104:678-684.

212. **Cohn JN**, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon A. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. *N Engl J Med* 1984;311:819-823.
213. Olivari MT, Garberg V, **Cohn JN**, Levine TB. Acute hemodynamic and hormonal response to indoramin, a new alpha₁ antagonist, in patients with congestive heart failure. *Clin Pharmacol Ther* 1984;36:297-301.
214. Petein M, Levine TB, **Cohn JN**. Hemodynamic effects of new inotropic agent, MDL 19205, in patients with chronic heart failure. *J Am Coll Cardiol* 1984;2:364-371.
215. Olivari MT, Levine TB, Weir EK, **Cohn JN**. Hemodynamic effects of Nifedipine at rest and during exercise in primary pulmonary hypertension. *Chest* 1984;86:14-19.
216. Goldsmith SR, Cowley AW, Francis GS, **Cohn JN**. Effect of increased intracardiac and arterial pressure on plasma vasopressin in humans. *Am J Physiol* 1984;246: H647-H651.
217. Levine TB, Olivari MT, **Cohn JN**. Hemodynamic and regional blood flow response to captopril in congestive heart failure. *Am J Med* 1984;76:38-42.
218. Pierpont GL, DeMaster EG, **Cohn JN**. Regional differences in adrenergic function with the left ventricle. *Am J Physiol* 1984;15:H824-H829.
219. Francis GS, Goldsmith SR, Pierpont G, **Cohn JN**. Free and conjugated plasma catecholamines in patients with congestive heart failure. *J Lab Clin Med* 1984;103: 393-398.
220. Ugurbil K, Petein M, Maidan R, Michurski S, **Cohn JN**, From AH. High resolution proton NMR studies of perfused rat hearts. *FEBS Letters* 1984;67:73-78.
221. Levine TB, Olivari MT, Garberg V, Sharkey SW, **Cohn JN**. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. *Circulation* 1984;69:548-553.
222. Francis GS, Olivari MT, Goldsmith SR, Levine TB, Pierpont G, **Cohn JN**. The acute response of plasma norepinephrine, renin activity, and arginine vasopressin to short-term nitroprusside and nitroprusside withdrawal in patients with congestive heart failure. *Am Heart J* 1983;106:1315-1320.
223. Morioka S, Simon G, **Cohn JN**. Cardiac and hormonal effects of enalapril in hypertension. *Clin Pharmacol Ther* 1983;34:583-589.
224. Pierpont GL, Francis GS, DeMaster EG, Levine TB, **Cohn JN**. Elevated myocardial dopamine in patients with pre-terminal congestive cardiomyopathy. *Am J Cardiol* 1983;52:1033-1035.

225. Goldsmith SR, Francis GS, Levine TB, Cowley AW, **Cohn JN**. Impaired response of plasma vasopressin to orthostatic stress in patients with congestive heart failure. *J Am Coll Cardiol* 1983;2:1080-1083.
226. Olivari MT, Carlyle PF, Levine TB, **Cohn JN**. Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure. *J Am Coll Cardiol* 1983;2:872-878.
227. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. *J Am Coll Cardiol* 1983; 2:755-763.
228. Olivari MT, Levine TB, **Cohn JN**. Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. *J Am Coll Cardiol* 1983;2:411-417.
229. Francis GS, Parks R, **Cohn JN**. The effects of bromocriptine in patients with congestive heart failure. *Am Heart J* 1983;106:100-106.
230. Gomes AS, Sinaiko AR, Tobian L, **Cohn JN**, Formanek G, Amplatz K: Hydralazine and the tourniquet test in renal vein renin sampling: A comparison. *Radiology* 1983;146:657-661.
231. Schwartz JS, **Cohn JN**, Bache RJ. Effects of coronary occlusion on flow in the distribution of a neighboring stenotic coronary artery in the dog. *Am J Cardiol* 1983;52:189-195.
232. Carlyle PF, **Cohn JN**. A non-surgical canine model of chronic left ventricular myocardial dysfunction. *Am J Physiol* 1983;244:H769-H774.
233. Goldsmith SR, Francis GS, Levine TB, **Cohn JN**. Regional blood flow response to orthostasis in patients with congestive heart failure. *J Am Coll Cardiol* 1983;1: 1391-1395.
234. Goldsmith SR, Francis GS, Cowley AW, Levine TB, **Cohn JN**. Increased plasma arginine vasopressin in patients with congestive heart failure. *J Am Coll Cardiol* 1983;1:1385-1390.
235. Pierpont GL, Levine TB, **Cohn JN**. Azotemia in patients with congestive heart failure treated with captopril. *Minnesota Medicine* 1983;66:223-225.
236. Levine TB, Francis GS, Goldsmith SR, **Cohn JN**. The neurohumoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure. *Circulation* 1983;67:1070-1075.
237. Franciosa JA, Wilen M, Ziesche S, **Cohn JN**. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. *Am J Cardiol* 1983;51:831-836.
238. Francis GS, Goldsmith SR, Ziesche SM, **Cohn JN**. Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. *Am J Cardiol* 1982;49:1152-1159.

239. Goldsmith SR, Francis GS, Cowley AW, **Cohn JN**. Response of vasopressin and norepinephrine to lower body negative pressure in humans. *Am J Physiol* 1982; 243:H970-H973.
240. Schwartz JS, Tockman B, **Cohn JN**, Bache RJ. Exercise-induced fall in flow through stenotic coronary arteries in the dog. *Am J Cardiol* 1982;50:1409-1413.
241. Levine TB, **Cohn JN**. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure. *Am Heart J* 1982;104:1159-1164.
242. Levine TB, **Cohn JN**. Factors predicting acute and long-term response to captopril therapy in congestive heart failure. *Br J Clin Pharmacol* 1982;14:169S-174S.
243. Francis GS, Goldsmith SR, **Cohn JN**. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. *Am Heart J* 1982;104:725-731.
244. Mashiro I, Mitsunami K, Kinoshita M, Kawakita S, Yamazaki G, Heckel R, Franciosa JA, **Cohn JN**. Left and right ventricular pressure diameter relationships during ventricular standstill in the dog. *Jpn Circ J* 1982;46:284-295.
245. Franciosa JA, Weber KT, Levine TB, Kinasevitz GT, Janicki JS, West J, Henis M, **Cohn JN**. Hydralazine in the long-term treatment of chronic heart failure: Lack of differences from placebo. *Am Heart J* 1982;104:587-594.
246. **Cohn JN**, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, Montero A, Cintron G, Clarke J, Hager D, Saunders R, Cobb F, Smith R, Loeb H, Settle H: Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. *New Engl J Med* 1982;306:1129-1135.
247. Levine TB, Francis GS, Goldsmith SR, Simon A, **Cohn JN**. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. *Am J Cardiol* 1982;49:1659-1666.
248. Morioka S, Simon G, **Cohn JN**. Echocardiographic assessment of left ventricular hypertrophy and function in renal hypertensive dogs. *Jap Circ J* 1982;46:143-150.
249. Levine TB, Franciosa JA, Vrobel T, **Cohn JN**. Hyponatraemia as a marker for high renin heart failure. *Br Heart J* 1982;47:161-166.
250. Mashiro I, Heckel RR, Nelson RR, **Cohn JN**, Franciosa JA. Site of premature ventricular contractions demonstrated by echocardiography. *Jpn Circ J* 1981;45: 532-538.
251. Pierpont GL, Francis GS, **Cohn JN**. Effect of captopril on renal function in patients with congestive heart failure. *Br Heart J* 1981;46:522-527.

252. Sharma B, Hoback J, Francis G, Hodges M, Asinger RW, **Cohn JN**. Pirbuterol: A new Oral sympathomimetic amine for the treatment of congestive heart failure. *Am Heart J* 1981;12:533-541.
253. **Cohn JN**, Levine TB, Francis GS, Goldsmith S. Neurohumoral control mechanisms in congestive heart failure. *Am Heart J* 1981;102:509-514.
254. Popkin MK, Mackenzie TB, Callies AL, **Cohn JN**. An interdisciplinary comparison of consultation outcomes. *Arch Gen Psychiatry* 1981;38:821-825.
255. Yasmineh WG, Yamada MK, **Cohn JN**. Post-synthetic variants of creatine kinase MM. *J Lab Clin Med* 1981;98:109-118.
256. Schwartz JS, Carlyle PF, **Cohn JN**. Decline in blood flow in stenotic coronary arteries during increased myocardial energetic demand in response to pacing-induced tachycardia. *Am Heart J* 1981;101:435-440.
257. Franciosa JA, **Cohn JN**. Effects of minoxidil on hemodynamics in patients with congestive heart failure. *Circulation* 1981;63:652-657.
258. Simon G, Franciosa JA, Gimenez HJ, **Cohn JN**. Short-term system hemodynamic adaptation of beta-adrenergic inhibition with atenolol in hypertensive patients. *Hypertension* 1981;3:262-268.
259. Mackenzie TB, Popkin MK, Callies AL, Jorgensen C, **Cohn JN**. The effectiveness of cardiology consultation: Concordance with diagnostic and drug recommendations. *Chest* 1981;79:16-22.
260. Limas C, Westrum B, Limas CJ, **Cohn JN**. Effect of salt on the vascular lesions of spontaneously hypertensive rats. *Hypertension* 1980;2:477-489.
261. Zobel LR, Finkelstein SM, Carlyle PF, **Cohn JN**. Pressure pulse contour analysis in determining the effect of vasodilator drugs on vascular hemodynamic impedance characteristics in dogs. *Am Heart J* 1980;100:81-88.
262. Moskowitz RM, **Cohn JN**. Hemodynamic effects of oxdralazine and hydralazine in hypertension. *Clin Pharmacol Ther* 1980;27:773-778.
263. Franciosa JA, Heckel R, Limas C, **Cohn JN**. Progressive myocardial dysfunction associated with increased vascular resistance. *Am J Physiol* 1980;239:H477-H482.
264. Franciosa JA, Goldsmith SR, **Cohn JN**. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. *Am J Med* 1980;69:559-566.

265. Schwartz JS, Carlyle PF, **Cohn JN**. Effect of coronary arterial pressure on coronary stenosis resistance. *Circulation* 1980;61:70-76.
266. Levine TB, Franciosa JA, **Cohn JN**. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. *Circulation* 1980;62:35-41.
267. Vrobel TR, **Cohn JN**. Comparative hemodynamic effects of converting enzyme inhibitor and sodium nitroprusside in severe heart failure. *Am J Cardiol* 1980;45: 331-336.
268. Pierpont GL, Franciosa JA, **Cohn JN**. Effect of prazosin on renal function in congestive heart failure. *Clin Pharmacol Ther* 1980;28:335-339.
269. Pierpont G, Hale KA, Franciosa JA, **Cohn JN**. Effects of vasodilators on pulmonary hemodynamics and gas exchange in left ventricular failure. *Am Heart J* 1980;99:208-216.
270. Franciosa JA, **Cohn JN**. Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. *Am J Cardiol* 1980;45:648-654.
271. Pierpont GL, Brown DC, Franciosa JA, **Cohn JN**. Effect of hydralazine on renal failure in patients with congestive heart failure. *Circulation* 1980;61:323-327.
272. Simon G, Franciosa JA, **Cohn JN**. Decreased venous distensibility in essential hypertension: Lack of systemic hemodynamic correlates. *Angiology* 1979;30:147-159.
273. Levine TB, **Cohn JN**, Vrobel T, Franciosa JA. High renin in heart failure: A manifestation of hyponatremia. *Trans Assoc Am Physicians* 1979;92:203-207.
274. Lebrech D, Kotelanski B, **Cohn JN**. Splanchnic hemodynamic factors in cirrhosis with refractory ascites. *J Lab Clin Med* 1979;93:301-309.
275. Franciosa JA, **Cohn JN**. Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure. *Circulation* 1979;59:1085-1091.
276. Schwartz JS, Carlyle PF, **Cohn JN**. Effect of dilation of the distal coronary bed on flow and resistance in severely stenotic coronary arteries in the dog. *Am J Cardiol* 1979;43:219-224.
277. **Cohn JN**, Mashiro I, Levine TB, Mehta J. Role of vasoconstrictor mechanisms in the control of left ventricular performance of the normal and damaged heart. *Am J Cardiol* 1979;44:1019-1022.
278. Franciosa JA, **Cohn JN**. Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. *Am J Cardiol* 1979; 43:1009-1014.

279. Franciosa JA, **Cohn JN**. Hemodynamic effects of oral ephedrine given alone or combined with nitroprusside infusion in patients with severe left ventricular failure. *Am J Cardiol* 1979;43:79-83.
280. Pierpont GL, **Cohn JN**, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. *Chest* 1978;73:8-13.
281. Franciosa JA, **Cohn JN**. Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure. *Am J Med* 1978;65:126-133.
282. Pierpont GL, **Cohn JN**, Franciosa JA. Congestive cardiomyopathy: Pathophysiology and response to therapy. *Arch Intern Med* 1978;138:1847-1850.
283. Franciosa JA, Notargiacomo AV, **Cohn JN**. Comparative haemodynamic and metabolic effects of vasodilator and inotropic agents in experimental myocardial infarction. *Cardiovasc Res* 1978;12:294-302.
284. Curtiss C, **Cohn JN**, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. *Circulation* 1978;58:763-770.
285. Franciosa JA, **Cohn JN**. Hemodynamic effects of trimazosin in patients with left ventricular failure. *Clin Pharmacol Ther* 1978;23:11-18.
286. **Cohn JN**, Franciosa JA. Selection of vasodilator, inotropic or combined therapy for the management of heart failure. *Am J Med* 1978;65:181-188.
287. Mashiro I, **Cohn JN**, Heckel R, Nelson RR, Franciosa JA. Left and right ventricular dimensions during ventricular fibrillation in the dog. *Am J Physiol* 1978; 235: H231-H236.
288. Franciosa JA, Blank RC, **Cohn JN**. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure. *Am J Med* 1978; 64:207-213.
289. Mehta J, Runge W, **Cohn JN**, Carlyle P. Myocardial damage after repetitive direct current shock in the dog: Correlation between left ventricular end-diastolic pressure and extent of myocardial necrosis. *J Lab Clin Med* 1978;91:272-279.
290. Franciosa JA, Nordstrom LA, **Cohn JN**. Nitrate therapy for congestive heart failure. *JAMA* 1978;240:443-446.
291. Schwartz JS, Ponto R, Carlyle P, Forstrom L, **Cohn JN**. Early redistribution of thallium-201 after temporary ischemia. *Circulation* 1978;57:332-335.
292. Schwartz JS, Ponto RA, Forstrom LA, Carlyle PF, McGregor LR, **Cohn JN**, Loken MK. Evaluation of early myocardial ischemia with thallium-201 in the pig. *Radiology* 1977;125:429-432.

293. Yasmineh WG, Pyle RB, **Cohn JN**, Nicoloff DM, Hanson NQ, Steele BW. Serial serum creatine phosphokinase MB isoenzyme activity after myocardial infarction: Studies in the baboon and man. *Circulation* 1977;55:733-738.
294. Franciosa JA, Notargiacomo AV, **Cohn JN**, Heckel RC. Importance of state of consciousness in determining hemodynamic responses to acute coronary occlusion in the dog. *Circulatory Shock* 1977;4:213-221.
295. Franciosa JA, Pierpont G, **Cohn JN**. Hemodynamic improvement after oral hydralazine in left ventricular failure: A comparison with nitroprusside infusion in 16 patients. *Ann Intern Med* 1977;86:388-393.
296. Franciosa JA, Blank R, **Cohn JN**, Mikulic E. hemodynamic effects of topical, oral and sublingual nitroglycerin in left ventricular failure. *Curr Ther Res* 1977;22:231-245.
297. Limas CJ, **Cohn JN**. Defective calcium transport by cardiac sarcoplasmic reticulum of spontaneously hypertensive rats. *Circ Res* 1977;40 (Suppl I): I62-I69.
298. Mikulic E, **Cohn JN**, Franciosa JA. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. *Circulation* 1977;56:528-533.
299. Mehta J, **Cohn JN**. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. *Circulation* 1977;55:370-375.
300. Mehta J, Wang Y, Lawrence C, **Cohn JN**. Aortic regurgitation associated with ventricular septal defect: Echocardiographic and hemodynamic observations. *Chest* 1977;71:784-786.
301. Mashiro I, Nelson R, **Cohn JN**, Franciosa JA. Ventricular dimensions measured noninvasively by echocardiography in the awake dog. *J Appl Physiol* 1976;41: 953-959.
302. Leichtman D, Nelson R, Gobel FL, Alexander CS, **Cohn JN**. Bradycardia with mitral valve prolapse: A potential mechanism of sudden death. *Ann Intern Med* 1976;85:453-457.
303. Lebrec D, Kotelanski B, **Cohn JN**. Splanchnic hemodynamics in cirrhotic patients with esophageal varices and gastrointestinal bleeding. *Gastroenterology* 1976;70: 1108-1111.
304. Mikulic E, Franciosa JA, **Cohn JN**. Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. *Circulation* 1975;52:477-482.
305. Akhtar N, Mikulic E, **Cohn JN**, Chaudhry MH. Hemodynamic effect of dobutamine in patients with severe heart failure. *Am J Cardiol* 1975;36:202-205.
306. Velasquez MT, Notargiacomo AV, **Cohn JN**. Sequential changes in intrarenal hemodynamics during saline infusion in the dog. *Am J Physiol* 1975;228:1663-1668.

307. **Cohn JN**, Mathew KJ, Franciosa JA, Snow JA. Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure. *Ann Intern Med* 1974;81:777-780.
308. Franciosa JA, Mikulic E, **Cohn JN**, Jose E, Fabie A. Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. *Circulation* 1974;50:1020-1024.
309. Guiha NH, **Cohn JN**, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. *N Engl J Med* 1974;291:587-592 .
310. Franciosa JA, Guiha NH, Limas CJ, Paz S, **Cohn JN**. Arterial pressure as a determinant of left ventricular filling pressure after acute myocardial infarction. *Am J Cardiol* 1974;34:506-512.
311. Gacad G, Akhtar N, **Cohn JN**. Orthostatic hypoxemia in a patient with bronchogenic carcinoma. *Arch Intern Med* 1974;134:1113-1115.
312. Franciosa JA, Notargiacomo A, **Cohn JN**. Systemic and regional hemodynamics after coronary embolization in closed chest dogs. *Circulatory Shock* 1974;1: 177-183.
313. Limas CJ, **Cohn JN**. Stimulation of vascular smooth muscle sodium, potassium-adenosine triphosphatase by vasodilators. *Circ Res* 1974;35:601-607.
314. Guiha NH, Limas CJ, **Cohn JN**. Predominant right ventricular dysfunction after right ventricular destruction in the dog. *Am J Cardiol* 1974;33:254-258.
315. **Cohn JN**, Guiha NH, Broder MI, Limas CJ. Right ventricular infarction: Clinical and hemodynamic features. *Am J Cardiol* 1974;33:209-214.
316. Limas CJ, Guiha NH, Lekagul O, **Cohn JN**. Impaired left ventricular function in alcoholic cirrhosis with ascites: Ineffectiveness of ouabain. *Circulation* 1974; 49: 754-760.
317. **Cohn JN**. Pharmacological manipulation of myocardial metabolism. *Bull NY Acad Med* 1974;50:328-340.
318. Limas CJ, **Cohn JN**. Alkaline phosphatase in vascular smooth muscle. *Nature (New Biol)* 1973;245:53-55.
319. Limas CJ, **Cohn JN**. Isolation and properties of myocardial prostaglandin synthetase. *Cardiovasc Res* 1973;7:623-628.
320. **Cohn JN**. Blood pressure and cardiac performance. *Am J Med* 1973;55:351-361.
321. **Cohn JN**. Vasodilator therapy for heart failure: The influence of impedance on left ventricular performance. *Circulation* 1973;48:5-8.

322. Logan A, Velasquez MT, **Cohn JN**. Renal cortical blood flow, cortical fraction and cortical blood volume in hypertensive subjects. *Circulation* 1973;47:1306-1312.
323. Kotelanski B, Groszmann RJ, **Cohn JN**. Positive inotropic effect of oral esproquin in normal subjects. *Clin Pharmacol Ther* 1973;14:427-433.
324. Limas CJ, Notargiacomo AV, **Cohn JN**. Effect of cyclic 3'5'-AMP on the (Na+K) – ATPase of myocardial sarcolemma. *Cardiovasc Res* 1973;7:477-481.
325. Limas CJ, **Cohn JN**. Regulation of myocardial prostaglandin dehydrogenase activity. The role of cyclic 3',5'-AMP and calcium ions (37214). *Proc Soc Exp Biol Med* 1973;142:1230-1234.
326. Velasquez MT, Notargiacomo AV, **Cohn JN**. Comparative effects of saline and mannitol on renal cortical blood flow and volume in the dog. *Am J Physiol* 1973; 224:322-327.
327. Sriussadaporn S, **Cohn JN**. Inotropic properties of an isoquinoline derivative (NC7197) in man. *Am Heart J* 1973;85:374-381.
328. Velasquez MT, Saini N, **Cohn JN**. Hypokalemia with normal blood pressure preceding malignant hypertension in a patient with primary aldosteronism (Conn's Syndrome). *Med Ann DC* 1972;41:732-735.
329. Groszmann RJ, Kotelanski B, **Cohn JN**, Khatri IM. Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. *Am J Med* 1972;53:715-722.
330. **Cohn JN**, Khatri IM, Groszmann RJ, Kotelanski B. Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique. *Am J Med* 1972;53:704-714.
331. Velasquez MT, Notargiacomo AV, **Cohn JN**. Influence of cortical plasma transit-time on p-aminohippurate extraction during induced renal vasodilation in anaesthetized dogs. *Clin Sci* 1972;43:401-411.
332. Broder MI, **Cohn JN**. Evolution of abnormalities in left ventricular function after acute myocardial infarction. *Circulation* 1972;46:731-743.
333. Kotelanski B, Groszmann RJ, **Cohn JN**. Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. *Gastroenterology* 1972;63:102-111.
334. Franciosa JA, Guiha NH, Limas CJ, Rodriguera E, **Cohn JN**. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. *Lancet* 1972;1:650-654.
335. Hamosh P, **Cohn JN**, Engleman K, Broder MI, Fries ED. Systolic time intervals and left ventricular function in acute myocardial infarction. *Circulation* 1972;45:375-381.

336. Groszmann RJ, Kotelanski B, **Cohn JN**. Different patterns of porta-systemic shunting in cirrhosis of the liver studied by an indicator dilution technique. *Acta Gastroenterol Latinoam* 1971;3:111-116.
337. **Cohn JN**, Velasquez MT, Notargiacomo AV, Khatri IM. Cortical blood flow, cortical fraction and cortical blood volume in the dog kidney. *Am J Physiol* 1971; 221:877-882.
338. Groszmann RJ, Kotelanski B, **Cohn JN**. Hepatic lobar distribution of splenic and mesenteric blood flow in man. *Gastroenterology* 1971;60:1047-1052.
339. Hamosh P, **Cohn JN**. Left ventricular function in acute myocardial infarction. *J Clin Invest* 1971;50:523-533.
340. Khatri IM, **Cohn JN**. Mechanism of exercise hypotension after sympathetic blockade. *Am J Cardiol* 1970;25:329-338.
341. Tristani FE, **Cohn JN**. Studies in clinical shock and hypotension. VII Renal hemodynamics before and during treatment. *Circulation* 1970;42:838-851.
342. Notargiacomo AV, **Cohn JN**. Contrasting degradation rates of synthetic angiotensin amide and natural angiotensin in human plasma. *Proc Soc Biol Med* 1970;134:149-151.
343. Tristani FE, **Cohn JN**. Studies in clinical shock and hypotension. VII Renal hemodynamics before and during treatment. *Circulation* 1970;42:838-851.
344. **Cohn JN**, Khatri IM, Hamosh P. Bedside catheterization of the left ventricle. *Am J Cardiol* 1970;25:66-69.
345. **Cohn JN**, Notargiacomo AV. Clinical application of a simple, specific bioassay technique for assay of renin activity. *Am J Med Sci* 1969;257:344-351.
346. **Cohn JN**, Pinkerson AL. Intrahepatic distribution of hepatic arterial and portal venous flows in the dog. *Am J Physiol* 1969;216:285-289.
347. **Cohn JN**, Tristani FE, Khatri IM. Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. *Am Heart J* 1969;78:318-330.
348. **Cohn JN**, Tristani FE. Studies in clinical shock and hypotension VI Relationship between left and right ventricular function. *J Clin Invest* 1969;48:2008-2018.
349. **Cohn JN**, Tristani FE, Khatri IM. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 in man. *Circulation* 1968;38:151-157.
350. **Cohn JN**, Pinkerson AL, Tristani FE. Mechanism of pulsus paradoxus in clinical shock. *J Clin Invest* 1967;46:1744-1755.

351. **Cohn JN**. Blood pressure measurement in shock: Mechanism of inaccuracy in auscultatory and palpatory methods. *JAMA* 1967;199:972-976.
352. **Cohn JN**, Luria MH, Daddario RC, Tristani FE. Studies in clinical shock and hypotension. V Hemodynamic effects of dextran. *Circulation* 1967;35:316-326.
353. Tristani FE, **Cohn JN**. Systemic and renal hemodynamics in oliguric hepatic failure: Effects of volume expansion. *J Clin Invest* 1967;46:1894-1906.
354. **Cohn JN**, Luria MH. Studies in clinical shock and hypotension. IV Variations in reflex vasoconstriction and cardiac stimulation. *Circulation* 1966;34:823-832.
355. **Cohn JN**. Paroxysmal hypertension and hypovolemia. *N Engl J Med* 1966;275:643-646.
356. **Cohn JN**. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. *Clin Sci* 1966; 30:267-278.
357. **Cohn JN**, Luria MH. Studies in clinical shock and hypotension. III Comparative effects of vasopressor drugs and dextran. *Arch Intern Med* 1965;116:562-566.
358. **Cohn JN**, Luria MH. Studies in clinical shock and hypotension. II Hemodynamic effects of norepinephrine and angiotensin. *J Clin Invest* 1965;44:1494-1504.
359. **Cohn JN**, Gombos EA. Unilateral renal hemodynamics studied by an indicator-dilution technic in man. *Am J Cardiol* 1965;16:820-827.
360. **Cohn JN**. Comparative cardiovascular effects of tyramine, ephedrine and norepinephrine in man. *Circ Res* 1965;16:174-182.
361. **Cohn JN**, Luria MH. Studies in clinical shock and hypotension. The value of bedside hemodynamic observations. *JAMA* 1964;190:891-896.
362. **Cohn JN**. Hepatorenal failure following portacaval shunt: Hemodynamic considerations and the application of ascitic fluid infusion. *Med Ann DC* 1964;33: 560-570.
363. Kot PA, Libertino JA, Fries ED, **Cohn JN**, Rose JC. Comparative effects of angiotensin and norepinephrine on arteries, veins and systemic vascular capacity in the dog. *Georgetown Med Bull* 1964;17:208-213.
364. **Cohn JN**, Liptak TE, Freis ED. Hemodynamic effects of guanethidine in man. *Circ Res* 1963;12:298-307.
365. Freis ED, **Cohn JN**, Liptak TE, Kovach A. Diastolic pressure and peripheral resistance during stellate ganglion stimulation. *Am J Physiol* 1963;204:71-72.
366. **Cohn JN**, Liptak TE, Freis ED. Comparison of colloidal chronic phosphate and BSP clearance methods for estimating hepatic blood flow. *Am Heart J* 1962;64:661-665.

367. Rose JC, Kot PA, **Cohn JN**, Freis ED, Eckert GE. Comparison of effects of angiotensin and norepinephrine on pulmonary circulation, systemic arteries and veins, and systemic vascular capacity in the dog. *Circulation* 1962;25:247-252.
368. **Cohn JN**, Sagall EL. Hemoglobinuria after massive intraperitoneal hemorrhage. *JAMA* 1959;170:1912-1915.

Other Peer Reviewed Publications

1. **Cohn JN**. Trials and tribulations. *J Card Fail* 2016; *J Card Fail*. 2016; in press. doi: 10.1016/j.cardfail.2016.01.001. [Epub ahead of print].
2. **Cohn JN**. Prevention of cardiovascular disease. *Trends Cardiovasc Med* 2015;25:436-442.
3. Florea VG, **Cohn JN**. The autonomic nervous system and heart failure. *Circ Res* 2014;114:1815-1826.
4. **Cohn JN**. Heart failure in 2013: Continue what we are doing to treat HF, but do it better. *Nat Rev Cardiol* 2014;11:69-70.
5. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, **Cohn JN**, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail* 2013;15:1082-1094.
6. **Cohn JN**. The message is clear: Prevent as well as treat acute myocardial infarction. *Circulation* 2013;128:2554-2556.
7. **Cohn JN**. Identifying the risk and preventing the consequences of cardiovascular disease. *Heart Lung Circulation* 2013;22:512-516.
8. **Cohn JN**. Preventing heart failure: a critique of strategies. *J Card Failure* 2013;19:211-213.
9. **Cohn JN**. Commentary: Fractional flow reserve-guided PCI reduced urgent revascularization at 7 months in coronary artery disease. *ACP Journal Club* 2012;157:JC5-9.
10. **Cohn JN**, Duprez DA. The problem with cardiovascular disease prevention guidelines. *Curr Treat Options Cardiovasc Med* 2012;14:571-574.
11. **Cohn JN**, Francis GS. Stage B, a precursor of heart failure, part II. *Heart Fail Clin* 2012;8:xv.

12. **Cohn JN**. What's in a name? Letter to the Editor. *J Card Fail* 2012;18:175.
13. **Cohn JN**, Francis GS. Stage B, a pre-cursor of heart failure. *Heart Fail Clin* 2012;8:xvii-xviii.
14. **Cohn JN**. Should the blood pressure or the blood vessel be the target of therapy? *Expert Review Cardiovasc Ther* 2011;9:1397-1401.
15. **Cohn JN**, McInnes GT, Shepherd AM. Direct-acting vasodilators. *J Clin Hypertension* 2011;13:690-692.
16. **Cohn JN**. Is activation of the renin-angiotensin system hazardous to your health? (Editorial). *Eur H Journal* 2011;32:2096-2097.
17. **Cohn JN**. Commentary for Review: Antihypertensive treatment prevents cardiovascular events and mortality in cardiovascular disease without hypertension. *ACP Journal Club* 2011;154:JC6-6.
18. **Cohn JN**. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. activation of the intrarenal renin-angiotensin system. *J Appl Physiol* 2010;109:2006-2007.
19. **Cohn JN**. Pharmacotherapy: Inhibiting LV remodeling-the need for a targeted approach. *Nat Rev Cardiol* 2011;8:248-249.
20. **Cohn JN**. President's Page. *Cardiovasc Drugs Ther* 2010;24:461.
21. **Cohn JN**. Cardiovascular pharmacotherapy 2010: foreword. *Cardiovasc Drugs Ther* 2010; 24:297.
22. **Cohn JN**. Role of the renin-angiotensin system in cardiovascular disease. *Cardiovasc Drugs Ther* 2010;24:341-44.
23. **Cohn JN**. Heart failure is preventable. *Curr Heart Fail Rep* 2010;7:91-92.
24. **Cohn JN**. Detecting the patient at risk of heart failure. *J Am Coll Cardiol* 2010;55:2138-9.
25. **Cohn JN**. Inotropic therapy for heart failure: paradise lost. *Eur Heart J* 2009;30:2965-2966.
26. **Cohn JN**, Duprez DA, Finkelstein SM. Comprehensive noninvasive arterial vascular evaluation. *Future Cardiol* 2009;5:573-579.
27. Giles TD, Materson BJ, **Cohn JN**, Kostis JB. Definition and classification of hypertension: an update. *J Clin Hypertension* 2009;11:611-614.

28. **Cohn JN.** The President's Page: Target response or target dose. *Cardiovasc Drug Ther* 2009;23:337.
29. **Cohn JN.** Conflicts of interest: to eliminate them or manage them. *J Card Failure* 2009;15:375-376.
30. **Cohn JN,** Cleland JGF, Lubsen J, Borer JS, Steg PG, Perelman M, Zannad F. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? *J Card Fail* 2009;15(3):199-205.
31. **Cohn JN.** ISCP President's Page. *Cardiovasc Drugs Ther* 2009;23:255-256.
32. **Cohn JN.** Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events? *Nat Clin Pract Cardiovasc Med.* 2008 Sep;5(9):526-7.
33. **Cohn JN.** Monitoring adherence to guidelines. *Circ Heart Failure* 2008;1:87-88.
34. Duprez DA, **Cohn JN.** Time to foster a rational approach to preventing cardiovascular morbid events. *J Am Coll Cardiol* 2008;52:327-329.
35. Exner DV, **Cohn JN.** Arguments prove nothing unless verified. A commentary on Kaufman's "Epidemiologic analysis of racial/ethnic disparities: Some fundamental issues and a cautionary example". *Social Science & Medicine* 2008;66(8):1675-1677.
36. **Cohn JN,** Goldman JM. Establishing a new option for target-organ protection: Rationale for ARB plus ACE inhibitor combination therapy. *Am J Hypertens* 2008;21(3):248-56.
37. **Cohn JN.** Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. *Adv Ther* 2007;24(6):1272-86.
36. **Cohn JN.** Review: Increased waist circumference or waist-to-hip ratio is associated with increased risk of cardiovascular events. *Evid Based Med* 2007;12(6):184.
37. **Cohn JN.** Myocardial structural effects of aldosterone receptor antagonism in heart failure. *J Am Coll Cardiol* 2007;50:597-599.
38. Duprez DA, **Cohn JN.** Arterial stiffness as a risk factor for coronary atherosclerosis. *Curr Atherosclerosis Rep* 2007;9:139-144.
39. Duprez DA, **Cohn JN.** Correspondence (Measuring endothelial function). *J of Hypertension* 2007;25:1513-14.
40. **Cohn JN.** Is it the blood pressure or the blood vessel? *J Amer Soc Hypertens* 2007;1(1):5-16.
41. **Cohn JN.** Letter to the Editor. Efficacy and Safety in Clinical Trials. *J Am Coll Cardiol* 2007;49(6):729.

42. **Cohn JN**. What is the role of angiotensin-receptor blockade in cardiovascular protection? *Am Heart J* 2006;152(5):859.E1-E8.
43. **Cohn JN**. The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial. *Journal of Law, Medicine & Ethics* 2006;34(3):552-554.
44. Duprez DA, **Cohn JN**. Monitoring vascular health beyond blood pressure. *Curr Hypertens Rep* 2006;8(4):287-91.
45. Lockhart CJ, McVeigh GE, **Cohn JN**. Measuring endothelial function. *Curr Diab Rep* 2006;6(4):267-73.
46. **Cohn JN**. Efficacy and safety in clinical trials in cardiovascular disease. *J Am Coll Cardiol* 2006;48(3):430-3.
47. **Cohn JN**, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. *Am J Cardiol* 2006;97(10A):4-12.
48. **Cohn JN**. B-type natriuretic peptide and artery stiffness. *Am J Hypertens* 2006;19(5):437-8.
49. **Cohn JN**. Arterial stiffness, vascular disease and risk of cardiovascular events. *Circulation* 2006;113(5):601-603.
50. Giles TD, Bradford BC, Black HR, **Cohn JN**, Kostis JB, Izzo JL, Weber MA on behalf of the Hypertension Writing Group. Expanding the definition and classification of hypertension. *J of Clin Hypertens* 2005;7(9):505-512.
51. **Cohn JN**. A-HeFT: Old dog, new endothelial tricks. *Texas Heart Institute Journal* 2005;32(3):366-368.
52. **Cohn JN**, Duprez DA, Grandits GA. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. *Hypertension* 2005 Jul;46(1):217-20.
53. Normand SL, Rector TS, Neaton JD, Pina IL, Lazar RM, Proestel SE, Fleischer DJ, **Cohn JN**, Spertus JA. Clinical and analytical considerations in the study of health status in device trials for heart failure. *J Card Fail* 2005, 11(5):396-403.
54. Richards AM, **Cohn JN**. N-terminal pro-brain natriuretic Peptide: a powerful biomarker of cardiac disease. *J Card Fail* 2005, 11(5 Suppl):1-2.
55. **Cohn JN**. New therapeutic strategies for heart failure: left ventricular remodeling as a target. *J Card Fail* 2004, 10(6 Suppl):S200-1.
56. Califf RM, Nissen SE, DeMaria AN, Ohman EM, Pitt B, Willerson JT, Bilheimer DW, **Cohn JN**, Feigal DW Jr, Hampson L, Lorell BH, Pepine CJ, Popp RL. Task force 2:

- Investigator participation in clinical research. *J Am Coll Cardiol* 2004 Oct 19;44(8):1729-36.
57. Neutel J, Weber M, Julius S, **Cohn JN**, Turlapaty P, Shen Y, Guo W, Batchelor A, Lagast H. Clinical experience with perindopril in elderly hypertensive patients. *Am J Cardiovas Drugs* 2004;4(5):335-41.
 58. **Cohn JN**, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. *Circulation* 2004;109(Suppl IV): IV31-IV46.
 59. **Cohn JN**, Mancini GBJ, Dahlöf B, Diez J. Surrogate markers for cardiovascular disease: structural markers. *Circulation* 2004;109(Suppl IV):IV22-IV30.
 60. **Cohn JN**. Introduction to surrogate markers. *Circulation* 2004;109(Suppl IV): IV20-IV-21.
 61. **Cohn JN**. Remodeling as an end-point in heart failure therapy. Editorial. *Cardiovasc Drugs Ther* 2004;18:7-8.
 62. **Cohn JN**. Clinical research: Whose agenda is it? *Circulation* 2004;109:2256-62.
 63. **Cohn JN**. Blood pressure and the therapy of advanced heart failure. Editorial. *J Am Coll Cardiol* 2004;21:1430-1.
 64. **Cohn JN**, Loscalzo J, Franciosa JA. Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction. *J Cardiac Fail* 2003 9 (5 Suppl Nitric Oxide):S197-8.
 65. Giles TD, Chatterjee K, **Cohn JN**, Colucci WS, Feldman AM, Ferrans VJ, Roberts R. Definition, classification, and staging of the adult cardiomyopathies: a prop for revision. *J Cardiac Fail* 2004;10:6-8.
 66. **Cohn JN**. Beta-blockers in heart failure. *J Cardiac Fail* 2003;9:458.
 67. Konstam MA, Udelson JE, Anand IS, **Cohn JN**. Ventricular remodeling in heart failure: a credible surrogate endpoint. *J Cardiac Fail* 2003;9:350-3.
 68. **Cohn JN**, Loscalzo J, Franciosa JA. Nitric oxide's role in heart failure: pathophysiology and treatment. Discussion. *J Cardiac Fail* 2003;9(Suppl 5):S205-9.
 69. **Cohn JN**. Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction. *J Cardiac Fail* 2003;9(Suppl 5):S197-8.
 70. Furman S, Alpert JS, **Cohn JN**, Timmis GC, The HEART Group. Management of potential conflict of interest during publication and presentation. *J Cardiac Fail* 2001;7: 367-368.
 71. **Cohn JN**. Val-HeFT: changing the heart failure horizon. *Eur Heart J*, 2003;5 (Suppl C):C25-C28.

72. McVeigh GE, **Cohn JN**. Endothelial dysfunction and the metabolic syndrome. *Curr Diab Rep*, 2003;3:87-92 .
73. **Cohn JN**. Angiotensin receptor blockers and clinical trials in heart failure. *Hotline Editorial. Eur Heart J*, 2003;24:125-6.
74. **Cohn JN**. Blood pressure and cardiovascular disease. *Bilingual J Hypertens* 2002;1:28-30.
75. Anand I, **Cohn JN**. Introduction. *J Cardiac Fail* 2002;8 (Suppl 6):S247.
76. **Cohn JN**. Global structural ventricular remodeling: Summation. *J Cardiac Fail* 2002;8 (Suppl 6):S269-270.
77. London GM, **Cohn JN**. Prognostic application of arterial stiffness: task forces. *Am J Hypertension* 2002;15:754-758.
78. **Cohn JN**. Sympathetic nervous system in heart failure. *Editorial. Circulation* 2002; 106:2417-2418.
79. **Cohn JN**. Lessons learned from the Valsartan-Heart Failure Trial (Val-HeFT): angiotensin receptor blockers in heart failure. *Am J Cardiol* 2002;90:992-993.
80. **Cohn JN**. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans. *Pro position. Curr Hypertension Reports* 2002;4:307-310.
81. **Cohn JN**. Hypertension therapeutic research: a plea for change in the new millennium. *Editorial. Am J Hypertension* 2002;15:97-98.
82. **Cohn JN**. Techniques for studying arterial elastic properties. *Letter to the Editor. Hypertension* 2002;39:e20.
83. **Cohn JN**, Tognoni G. Reply to Letter to the Editor. *N Engl J Med* 2002;346:1174.
84. Furman S, Alpert JS, **Cohn JN**, Timmis GC. The HEART Group. Management of potential conflict of interest during publication and presentation. *J Cardiac Fail* 2001;7:367-368.
85. **Cohn JN**. Looking back and looking forward. *Editorial. J Cardiac Fail* 2001;7: 286-288.
86. **Cohn JN**. Hormones, drugs, remodeling and outcome in heart failure and after myocardial infarction. *Editorial. Cardiovasc Drugs & Therapy* 2001;15:9-10.

87. **Cohn JN**. Editorial. Open label randomized trial of torsemide compared with furosemide in patients with heart failure. *Am J Med* 2001;111:577.
88. **Cohn JN**. Optimal diuretic therapy for heart failure. Editorial. *Am J Med* 2001; 111:577.
89. **Cohn JN**. The surrogate specialist: essential but inadequate. Editorial. *J Cardiac Fail.* 2001;7:219-20.
90. **Cohn JN**. The fallacy of the mean. Editorial. *J Cardiac Fail* 2001;7:103-104.
91. Nicklas JM, **Cohn JN**, Pitt B. What does ATLAS really tell us about “high” dose angiotensin-converting enzyme inhibition in heart failure? [Review] *J Cardiac Fail* 2000;6:165-168.
92. **Cohn JN**. Left ventricle and arteries: structure, function, hormones, and disease. *Hypertension* 2001;37(part 2):346-349.
93. **Cohn JN**. Anti-intellectualism in clinical cardiovascular medicine. Editorial. *J Cardiac Fail* 2000;6:287-289.
94. **Cohn JN**. Rationale for angiotensin II receptor blocker therapy in chronic heart failure. *Jrnl Renin-Angiotensin-Aldosterone System* 2000;1(Suppl 1):S38-40.
95. **Cohn JN**, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice. A contemporary review by the National Council on Potassium in Clinical Practice. *Archives Int Med* 2000;160:2429-2436.
96. **Cohn JN**. Experience with expedited reviews. Editorial. *J Cardiac Failure* 2000;6:2.
97. **Cohn JN**. On scientific language. Editorial. *J Cardiac Failure* 2000;6:1.
98. **Cohn JN**. Lumpers versus splitters. Editorial. *J Cardiac Fail* 2000;6:75-76.
99. **Cohn JN**: Heart failure: future treatment approaches. *Am J Hypertension* 2000;13:74S-78S.
100. **Cohn JN**. ACE inhibition and vascular remodeling of resistance vessels. Vascular compliance and cardiovascular implications. *Heart Disease* 2000;2:S2-S6.
101. **Cohn JN**. Prevention of heart failure in hypertensive patients. Review. *Harrison's Online*. <http://www.harrissonsonline.com>, 2000.
102. **Cohn JN**, Ferrari R, Sharpe N, on Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol* 2000; 35:569-582.

103. **Cohn JN**. HOPE for an ACE inhibitor. Editorial. *J Cardiac Fail* 1999;5:290-291.
104. **Cohn JN**: From hypertension to heart failure. *Euro Heart J* 2000;2(SupplA):A2-A5.
105. Califf RM, **Cohn JN**. Cardiac protection: evolving role of angiotensin receptor blockers. *Am H Jnl* 2000, 139(Suppl 1):S15-S22.
106. **Cohn JN**. Prevention of heart failure. *Cardiology* 1999;92(Suppl 1):22-25.
107. **Cohn JN**. Vascular wall function as a risk marker for cardiovascular disease. *J Hypertension* 1999;17(Suppl 5):S41-4.
108. **Cohn JN**: Arterial stiffness. [Letter] *J Hypertension* 1999, 17:1227.
109. **Cohn JN**. Exercise tolerance as a guide to therapeutic efficacy for heart failure. The potential for angiotensin receptor blockers Editorial. *Circulation* 1999; 100:2208-2209.
110. **Cohn JN**. Innovation and clinical practice in an era of polypharmacy for heart failure. *J Cardiac Fail* 1999;5:175-177.
111. **Cohn JN**. The angiotensin receptor blockers. Editorial. *J Cardiac Fail* 1999;5:77-78.
112. **Cohn JN**. Improving outcomes in congestive heart failure: Val-HeFT. *Cardiology* 1999;91(suppl 1):19-22.
113. **Cohn JN**. Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. *Progress in Cardiovascular Diseases* 1999;41: 441-450.
114. 30th Bethesda Conference: The future of academic cardiology. *J Am Coll Cardiol* 1999, 33: 1096-1135.
115. **Cohn JN**: Author reply to letters to the Editor. *N Engl J Med* 1999;340:1512.
116. **Cohn JN**. Is there a common mechanism of benefit for effective treatment of heart failure? Editorial. *Euro J Heart Fail*, 1999;1:31-34.
117. **Cohn JN**. Addressing the heart failure management gap. Editorial. *J Cardiac Fail*, 1999;5:1-2.
118. Clement DL, **Cohn JN**. Salvaging the history, physical examination and doctor-patient relationship in a technological cardiology environment. Viewpoint. *J Am Coll Cardiol*, 1999;33:892-893.

- 119.**Cohn JN**. Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice. *J Cardiovasc Pharmacology* 1998;32 (Suppl 3):S38-S40.
- 120.Consensus recommendations for the management of chronic heart failure. Guest Editors: M Packer and JN Cohn, on behalf of the Advisory Council to Improve Outcomes Nationwide in Heart Failure (ACTION HF). *Am J Cardiol* 1999; 83(2A):1A-38A.
- 121.**Cohn JN**. Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension. *J Hypertension*, 1998;16:2117-2124.
- 122.**Cohn JN**. Improving outcomes in heart failure. Editorial. *Euro Heart J* 1998; 9: 1124-1125.
- 123.**Cohn JN**. Beta-blockers in heart failure. *European Heart J* 1998; 19 (Suppl F): F52-F-55.
- 124.**Cohn JN**. Intent-to-treat: a curse of clinical trials. Editorial. *J Cardiac Fail* 1998;4:1-2.
- 125.**Cohn JN**. Nitrates in left ventricular dysfunction and congestive heart failure. *Am J Cardiol* 1998;81(Suppl 1A):54A-56A.
126. Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AJ, Morgan DJ, **Cohn JN**. Vascular compliance and cardiovascular disease: a risk factor or a marker? *Am J Hypertension*, 1997;10:1175-1189.
- 127.**Cohn JN**. Industry, academia, and postgraduate education. Editorial. *J Cardiac Fail* 1997;3:245-247.
- 128.**Cohn JN**. Overview of the treatment of heart failure. *Am J Cardiol* 1997;80 (Suppl 11L):2L-6L.
- 129.Buhler FR, **Cohn JN**, Hermesmeyer K, Menard J, Abernethy DR, Kobrin I, Pratt CM. New strategies in cardiovascular disease management: summary of round table discussion. *J Hypertension* 1997;15:S1-S3.
- 130.Cohn **JN**. How can clinical studies and large-scale intervention trials help optimise individually targeted therapy. *Intl J Clin Prac*, Nov 1997 (Suppl 92): 74-75.
- 131.**Cohn JN**. The mysterious angiotensin-converting enzyme inhibitors. Editorial. *J Cardiac Fail* 1997;3:161-163.
- 132.**Cohn JN**, Bristow MR, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. *Circulation* 1997;95:766-770.

- 133.**Cohn JN**. Jugular venous pressure monitoring: a lost art? Editorial. *J Cardiac Fail*, 1997;3:71-73.
- 134.**Cohn JN**. Prognostic value of assessment of cardiac failure. *Medicographica* 1997; 19:29-31.
- 135.**Cohn JN**. Current concepts in the treatment of congestive heart failure. *Cardiology* 1997; 88(Suppl 2):2-6.
- 136.**Cohn JN**. The joy of discovery. Editorial. *J Cardiac Fail* 1997;3:1-2.
- 137.**Cohn JN**. Prognosis in congestive heart failure. *J Cardiac Fail* 1996;2:S225-S229.
- 138.**Cohn JN**. Slowing the progression of heart failure. Hotline Editorial. *Eur Heart J* 1996;17:1609-1611.
- 139.Premen AJ, for the NIA Cardiovascular Aging Advisory Panel. Research recommendations for cardiovascular aging research. *JAGS* 1996;44:1114-1117.
- 140.**Cohn JN**. Evidence-based medicine: What is the evidence? Editorial. *J Cardiac Fail* 1996;2:159-161.
- 141.**Cohn JN**. Is there a role for endothelin in the natural history of heart failure? Editorial. *Circulation* 1996;94:604-606.
- 142.**Cohn JN**. Information vs Knowledge. Editorial. *J Cardiac Fail* 1996;2:67-69.
- 143.**Cohn JN**. The management of chronic heart failure. Reply. *N Engl J Med* 1997;336:296.
- 144.**Cohn JN**. Drug Therapy: The management of chronic heart failure. *N Engl J Med* 1996; 335:490-498.
- 145.Forrester JS, Merz CNB, Bush TL, **Cohn JN**, Hunninghake DB, Parthasarathy S, Superko HR. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. *J Am Coll Cardiol* 1996;27: 991-1006.
- 146.**Cohn JN**. Left ventricular dysfunction and heart failure mechanistic and therapeutic distinctions. *Clin Exp Hypertension*. Marcel Dekker, Inc., New York. 1996; 18 (3&4):559-568.
- 147.**Cohn JN**. Left ventricular remodeling and neurohormonal stimulation as markers for mortality and response to therapy in heart failure. *Shinzo (Japanese Heart)* 1995;27(6):590-597.

- 148.**Cohn JN**. ACE inhibitors in non-ischaemic heart failure: results from the MEGA trials. *European Heart J* 1995, 16:133-136 .
- 149.Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G, for the meeting participants. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. *Circulation* 1995;92:3132-3137.
- 150.**Cohn JN**. Structural changes in cardiovascular disease. *Am J Cardiol* 1995; 76 (Suppl E):34E-37E.
- 151.**Cohn JN**. Introduction. *Am J Cardiol* 1995; 76 (Suppl E): 1E-2E.
- 152.**Cohn JN**. Critical review of heart failure: the role of left ventricular remodeling in the therapeutic response. *Clin Cardiol* 1995;9(Suppl 4):4-12.
- 153.**Cohn JN**. Survival benefits from ACE inhibitors in patients with heart failure. *Clin Cardiol* 1995;9:30-33.
- 154.**Cohn JN**, Francis GS. Cardiac failure: a revised paradigm. Editorial. *J Cardiac Fail* 1995;1:261-266.
- 155.**Cohn JN**. Plasma norepinephrine and mortality. *Clin Cardiol* 1995;18(Suppl I):I9-12.
- 156.**Cohn JN**. New concepts regarding events that lead to end-stage heart disease. *Cardiovasc Drugs Ther* 1995;9:489-492.
- 157.**Cohn JN**. Introduction. *Clin Cardiol* 1995;18(Suppl I):I1-2.
- 158.**Cohn JN**. Mortality as an endpoint for cardiac failure therapy. Editorial. *Jrnl Cardiac Failure* 1995;1:191-194.
- 159.**Cohn JN**. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Editorial. *Circulation* 1995;91:2504-2507.
- 160.**Cohn JN**. Who should treat cardiac failure? Editorial. *Jrnl Cardiac Failure* 1995;1: 97-99.
- 161.Francis GS, McDonald K, Chu C, **Cohn JN**. Pathophysiologic aspects of end-stage heart failure. *Am J Cardiol* 1995;75:11A-16A.
- 162.**Cohn JN**. The rationale for new agents in the treatment of congestive heart failure. *Congestive Heart Failure* 1995;Jan/Feb:36-39.
- 163.**Cohn JN**. Physiologic rationale for co-treatment with diuretics in heart failure. *Brit Heart J* 1994;72 (Sup 2):63-67.
- 164.**Cohn JN**. Commentary. Heart failure: Evaluation and care of patients with left-ventricular systolic dysfunction. *Abstracts of Clinical Care Guidelines*. 1994;6:7-8.

165. Tobian L, Brunner HR, **Cohn JN**, Gavras H, Laragh JH, Materson BJ, Weber MA. Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. *Am J Hypertension* 1994;7:859-872.
166. **Cohn JN**. Vasodilators in heart failure: conclusions from V-HeFT II and rationale for V-HeFT III. *Drugs* 1994, 47 (Suppl 4):47-58.
167. **Cohn JN**. Treatment of infarct related heart failure: vasodilators other than ACE inhibitors. Invited Editorial. *Cardiovasc Drugs and Therapy* 1994;8:119-122.
168. **Cohn JN**. Has the problem of heart failure been solved? *Am J Cardiol* 1994;73:40B-43B.
169. Rector TS, **Cohn JN**. Prognosis in congestive heart failure. *Annu Rev Med* 1994, 45:341-350.
170. **Cohn JN**. Prevention of heart failure. *Heart Disease and Stroke* 1994;3:5-8.
171. Weber KT, Brilla CG, Cleland JGF, **Cohn JN**, Hansson L, Heagerty AM, Laragh JH, Laurent S, Ollivier JP, Pauletto P, Pouleur H, Smits JFM, Tan LB. Cardioreparation and the concept of modulating cardiovascular structure and function. *Blood Pressure* 1993;2:6-21.
172. Cohn JN. Introduction: Contribution of ACE inhibition to the management of heart failure. *Am Heart J* 1993;126:755.
173. McDonald KM, Cohn JN. Left ventricular mass and volume after myocardial infarction. Letter to the Editor. *JACC* 1993;22:2059-2060
174. Cohn JN. Efficacy of vasodilators in the treatment of heart failure. *JACC* 1993, 22:135A-138A.
175. **Cohn JN**. Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure. *Am J Cardiol* 1993;72:21C-26C.
176. **Cohn JN**. ACE Inhibitors. Editorial. *Cardiovasc Drugs & Therapy* 1993;7:379.
177. **Cohn JN**. Tele-Lecture: Highlights and clinical relevance of the V-HeFT trials. *Cong HF Index & Rev* 1993;5:10-11.
178. **Cohn JN**. Physiologic variables as markers for symptoms, risk, and interventions in heart failure. *Circulation*, 1993;87:VII-110-114.
179. **Cohn JN**. The Vasodilator-Heart Failure Trials (V-HeFT): Introduction. *Circulation* 1993;87:VI-1-4 .
180. **Cohn JN**. Post-MI remodeling. *Clin Cardiol* 1993 16;II-21 - II-24.
181. Francis GS, McDonald KM, **Cohn JN**. Neurohumoral activation in pre-clinical heart failure: Remodeling and the potential for intervention. *Circulation* 1993;87:IV-90-96.

- 182.**Cohn JN**. The V-HeFT Trials. *Heart Failure* 1993;9:8-13.
- 183.McVeigh GE, Finkelstein SM, **Cohn JN**. Assessment of arterial compliance in hypertension. *Curr Opin Nephrology & Hypertension* 1993;2:82-86.
- 184.**Cohn JN**, Lüscher TF. Circulation and hemodynamics: Editorial overview. *Curr Opin Nephrology & Hypertension* 1993;2:73-76.
- 185.**Cohn JN**. Treatment of heart failure in the elderly. *High Blood Pressure & Cardiovascular Prev* 1992;1:172-173.
- 186.**Cohn JN**. Cardiovascular disease and care in the elderly: current status in the United States. *High Blood Pressure & Cardiovascular Prev* 1992;1:117.
- 187.**Cohn JN**. Pharmacologic mechanisms of nitrates in ischemic heart disease. *Am J Cardiol* 1992;70:38G-42G.
- 188.Yaginuma T, **Cohn JN**. Introduction to wave reflection, wave travel and changes with modification of geometric and physical parameters. *J Hypertension* 1992;10:S71-72.
- 189.**Cohn JN**. Mechanisms of action and efficacy of nitrates in heart failure. *Am J Cardiol* 1992;70:88B-92B.
- 190.**Cohn JN**. Prevention of Heart Failure: A New Agenda. Editorial. *N Engl J Med* 1992;327:725-727.
- 191.**Cohn JN**: Reply to letter to the editor. *N Engl J Med* 1992;326:1221.
- 192.**Cohn JN**. Role of neurohumoral control of the circulation in determining exercise capacity in patients with heart failure. *Chest* 1992;101:S347-S349.
- 193.Pitt B, **Cohn JN**, Francis GS, Kostis JB, Packer M, Pfeffer MA, Swedberg K, Yusuf S: The effect of treatment on survival in congestive heart failure. *Clin Cardiol* 1992;15: 323-329.
- 194.**Cohn JN**, ed: Contemporary issues in heart failure. Monograph: Proceedings of Opinion Leaders' Symposium, September 15, 1990, Westfields, VA. Health Learning Systems Inc., 1991.
- 195.Dzau V, Braunwald E, and participants Boston, MA and participating centers: Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. *Am Heart J* 1991;121:1244-1263.
- 196.**Cohn JN**. Lessons from V-HeFT: Questions for V-HeFT II and the future therapy of heart failure. *Herz* 1991;16:267-271.
- 197.**Cohn JN**. Future directions in vasodilator therapy for heart failure. *Am Heart J* 1991;121:969-973.

- 198.**Cohn JN**. The role of α_1 -selective blockade in the management of hypertension and congestive heart failure. *J Vas Med & Biol* 1990;2:262-267.
- 199.**Cohn JN**, Rajfer SF Evaluation of functional capacity in heart failure: A consensus conference. *Heart Failure* 1990;6:169-173.
- 200.**Cohn JN**. Statistical significance of V-HeFT results. Editorial. *Am J Cardiol* 1990; 66:1507-1508.
- 201.Francis GS, **Cohn JN**. Heart failure: Mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. Reviews. *FASEB* 1990;4:3068-3075.
- 202.**Cohn JN**. Editorial comments. *Hepatology Elsewhere* 1990;11:510-511.
- 203.**Cohn JN**. Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition. *Am J Cardiol* 1990;66(Suppl):2D-6D.
- 204.**Cohn JN**. Introduction. A symposium: Angiotensin-converting enzyme inhibition therapy in the treatment of congestive heart failure. *Am J Cardiol* 1990;66(Suppl):1D.
- 205.**Cohn JN**. Nitrates are effective in the treatment of chronic congestive heart failure: The protagonist's view. *Am J Cardiol* 1990; 66: 444-446.
- 206.Cohn JN. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. *Circulation* 1990; 82 (Suppl I): I59-I67.
- 207.**Cohn JN**:Neuroendocrine activation after acute myocardial infarction. *Am J Cardiol* 1990; 65: I28-I31.
- 208.**Cohn JN**. Treatment of patients with heart failure: Letters to the editor. *Circulation* 1990;81:1440-1441.
- 209.**Cohn JN**, Campbell RWF. Introduction: The role of the adrenergic system in heart failure. *Eur Heart J* 1990; 11 (Suppl A): 1.
- 210.**Cohn JN**. Sympathetic nervous system activity and the heart. *Am J Hypertension*, 1989; 2: 3535-3565.
- 211.**Cohn JN**. Prognostic factors in heart failure: Poverty amidst a wealth of variables. *J Am Coll Cardiol*, 1989; 14: 571-572.
- 212.**Cohn JN**. Left ventricular function after myocardial infarction. *J Cardiovasc Pharmacol* 1989; 14 (Suppl 9): S55-S58.
- 213.**Cohn JN**. Unloading the failing heart. Previous experience and future directions. *Am J Hypertension* 1989; 2: 736-739.

- 214.**Cohn JN**. The sympathetic nervous system in heart failure. *J Cardiovasc Pharmacol* 1989; 14 (Suppl 5): S57-S61.
- 215.**Cohn JN**. Inotropic therapy for heart failure: Paradise postponed. *N Engl J Med* 1989; 11: 729-731.
- 216.**Cohn JN**. An explanation for varying views about digitalis efficacy in congestive heart failure. *Cardiovascular Drugs and Therapy* 1989;3:19-20.
- 217.**Cohn JN**. Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? Antagonist's viewpoint. *J Am Col Cardiol* 1988; 12: 554-558.
- 218.**Cohn JN**. Current therapy of the failing heart. *Circulation* 1988; 78: 1099-1107.
- 219.**Cohn JN**, Rector TS. Vasodilator therapy for heart failure: What have we learned from controlled clinical trials? *JAMA* 1988; 259: 3456-3457.
- 220.Kubo SH, Olivari MT, **Cohn JN**. Calcium antagonists in heart failure. *Ann NY Acad Sci* 1988; 522: 553-564.
- 221.**Cohn JN**. Current therapy for heart failure. *Am J Med* 1988; 84: 51-55.
- 222.**Cohn JN**. Quantitative exercise testing for the cardiac patient: The value of monitoring gas exchange. *Circulation* 1987; 76(Suppl VI): VI1-VI2.
- 223.**Cohn JN**. Congestive heart failure: Is the heart or periphery at fault? *Cardiovasc Drugs and Therapy* 1987; 1: 191-193.
224. **Cohn JN**. Role of nitrates in congestive heart failure. *Am J Cardiol* 1987;60:39H-43H.
225. **Cohn JN**. Role of drugs for systemic hypertension and their effect on the heart. *Am J Cardiol* 1987; 60: 72G-74G.
226. **Cohn JN**. Role of drugs for systemic hypertension and their effect on the heart. *Am J Cardiol* 1987; 60: 72G-74G.
227. Levine TB, Olivari MT, **Cohn JN**. Angiotensin converting enzyme inhibitors in congestive heart failure. *Am J Med* 1986;81:36-39.
228. **Cohn JN**. Nervous system control mechanisms in heart failure. *Acta Med Scand* 1986;61:15-20.
229. **Cohn JN**. Implications from the Veterans Administration Cooperative Study on vasodilator therapy of heart failure. *Heart Failure* 1986;2:151-155.

230. **Cohn JN**. Calcium antagonists and left ventricular function: Effects of nitrendipine in congestive heart failure. *Am J Cardiol* 1986;58:27D-30D.
231. **Cohn JN**. Rationale for α -blockade in congestive heart failure. *J Cardiovasc Pharmacol* 1986; 8(Suppl 2): S98-S101.
232. **Cohn JN**. Vasodilator therapy of dilated cardiomyopathy. *Postgrad Med J* 1986;62: 599-600.
233. Francis GS, **Cohn JN**. The autonomic nervous system in congestive heart failure. *Ann Rev Med* 1986;37:235-247.
234. Finkelstein SM, **Cohn JN**, Carlyle PF, Carlyle WJ. Vascular compliance in congestive heart failure. *Proceedings of the Seventh Annual Conference of the IEEE Engineering in Medicine and Biology Society, Chicago, Illinois, 1986*, pp. 550-553.
235. Matangi MF, **Cohn JN**. The nuclear stethoscope. *NZ Med J* 1985;28:686-689.
236. **Cohn JN**. Clinical implications of the hemodynamic effects of beta blockade. *Am J Cardiol* 1985;55:125D-128D.
237. **Cohn JN**. Bepridil symposium. Introduction: Symposium on bepridil: A new antianginal agent. *Am J Cardiol* 1985;55:1c-62c.
238. **Cohn JN**. AJC 25 years ago. *Am J Cardiol* 1985;55:867-868.
239. **Cohn JN**. Unloading the heart in congestive heart failure. *Am J Med* 1984;77:67-70.
240. **Cohn JN** (Editor): New concepts in the mechanisms and treatment of congestive heart failure. *Am J Cardiol* 1985;55:1A-47A.
241. **Cohn JN**. Treatment by modification of circulatory dynamics. *Hospital Practice* 1984;9:37-51.
242. Francis GS, Goldsmith SR, Levine TB, Olivari MT, **Cohn JN**. The neurohumoral axis in congestive heart failure. *Ann Intern Med* 1984;101:370-377.
243. Schneider JR, Alyono D, Schwartz JS, Levine TB, **Cohn JN**, Molina JE, Anderson Najarian JS, Bolman RM. Human cardiac transplantation at the University of Minnesota. *Minnesota Medicine* 1984;67:209-211.
244. **Cohn JN**. Digitalis in heart failure. *JAMA* 1984;251:1489.
245. Simon G, Morioka S, Snyder DK, **Cohn JN**. Increased renal plasma flow during long-term antihypertensive therapy with enalapril. *Clin Pharmacol and Ther* 1983; 459-465.

246. Olivari MT, **Cohn JN**. Cutaneous administration of nitroglycerin: a review. *Pharmacotherapy* 1983;3:149-157.
247. **Cohn JN**. Calcium, vascular smooth muscle and calcium entry blockers in hypertension. *Ann Int Med* 1983; 8:806-809.
248. **Cohn JN**. Eclecticism in a passionate profession. *Circulation* 1983;67:960-961.
249. **Cohn JN**. Haemodynamic effects of beta blockers. *Drugs* 1983;25(Suppl 2):100-102.
250. **Cohn JN**. Calcium-entry blockers in coronary artery disease: Introduction. *Circulation* 1982;65(Suppl I):1-2.
251. **Cohn JN**, Levine TB. Angiotensin-converting enzyme inhibition in congestive heart failure: The concept. *Am J Cardiol* 1982;49:1480-1483.
252. **Cohn JN**. Vasodilator therapy: Implications in acute myocardial infarction and congestive heart failure. *Am Heart J* 1982;103:773-778.
253. **Cohn JN**, Mehta J, Francis GS. A review of the haemodynamic effects of labetalol in man. *Brit J Clin Pharmacol* 1982;13:19-26.
254. **Cohn JN**. Science and advertising. *Circulation* 1982;65:839-840.
255. **Cohn JN**. Vasodilator therapy of congestive heart failure. *Advances in Internal Medicine* 1981;26:293-315.
256. **Cohn JN**. Vasodilator Symposium. Introduction: Marriage of the heart and the peripheral circulation. *Progress in Cardiovascular Diseases* 1981;24:189-190.
257. **Cohn JN**. Physiologic basis of vasodilator therapy for heart failure. *Am J Med* 1981; 71:135-139.
258. **Cohn JN**. Progress in vasodilator therapy for heart failure. *N Engl J Med* 1980;302: 1414-1416.
259. **Cohn JN**. Vasodilators in congestive heart failure. *Circulation* 1980;61:661-663.
260. **Cohn JN**, Burke LP. Diagnosis and treatment - Drugs five years later: Nitroprusside. *Ann Intern Med* 1979;91:752-757.
261. Schlant RC, **Cohn JN**. Complicated myocardial infarction with chronic pulmonary disease. Problems in management. *Chest* 1979;75:178-181.
262. **Cohn JN**. Right ventricular infarction revisited. *Am J Cardiol* 1979;43:666-668.

- 263.**Cohn JN**, Franciosa JA. Vasodilator therapy of cardiac failure. N Engl J Med 1977; 297: 27-31 and 254-258.
- 264.**Cohn JN**. Vasodilator therapy of myocardial infarction. (Editorial) N Engl J Med 1974;290:1433-1434.
- 265.**Cohn JN**. Hypertension - 1974. Arch Intern Med 1974;133:911-913.
- 266.**Cohn JN**, Limas CJ, Guiha N. Hypertension and the heart. Arch Intern Med 1974; 133:969-979.
- 267.**Cohn JN**. Indications for digitalis therapy – A new look. JAMA 1974;229:1911-1914.
- 268.**Cohn JN**. Monitoring techniques in shock. Am J Cardiol 1970;26:565-569.
- 269.**Cohn JN**. Central venous pressure as a guide to volume expansion. Ann Intern Med 1967;66:1283-1287.
- 270.**Cohn JN**. Myocardial infarction shock revisited. Am Heart J 1967;74:1-3.

Non-Peer-Reviewed Publications

- 1.**Cohn JN**. Letter to Margaret Anderson. The Physiologist 2010;53:181-182.
- 2.**Cohn JN**. President's Page: ISCP's educational goals. Cardiovasc Drugs Ther 2010;24:89.
- 3.**Cohn JN**. President's Page: Beijing 2009. Cardiovasc Drugs Ther 2009;23:419-423.
- 4.**Cohn JN**. In Memorium – Louis Tobian. J Amer Soc Hypertens 2007;1(1):3-4.
- 5.**Cohn JN**. Guest Editorial: Differentiation in the field of cardiology. Cardiology Quarterly November 2006.
- 6.**Cohn JN**. Commentary: B-type natriuretic peptide level had reduced specificity for diagnosing heart failure in dyspnea with atrial fibrillation in the emergency department. ACP J Club 2006;144(2):48.
- 7.**Cohn JN**. Review: concomitant aspirin use does not reduce the effectiveness of ACE inhibitors. ACP J Club 2003;138:64.
- 8.**Cohn JN**, Velazquez EJ, Musher J. Symposium reporter 2003. New therapeutic options in the management of hypertension to heart failure. Orlando, Florida, March 6, 2003. J Am Med Dir Assoc 2003;1-16.
- 9.**Cohn JN**. Arterial elasticity. Minnesota Physician 1999;13:28-29.
- 10.**Cohn JN**. Prevention of congestive heart failure. Am Family Physician 1998;57: 1901-1904.

11. **Cohn JN**. Heart failure – physiology and treatment considerations. *Today's Therapeutic Trends* 1997;14(4):197-206.
12. Patel SS, **Cohn JN**, Willerson JT, Eds: *Handbook of Cardiovascular Clinical Trials*. Churchill Livingstone Inc., New York, 1997.
13. **Cohn JN**. Treatment of heart failure II. ACE Inhibition and Your Practice, No. 36. *Current Science Ltd.*, 1992.
14. Francis GS, **Cohn JN**. Catecholamines in Cardiovascular Disease. *Current Concepts*. The Upjohn Company, Kalamazoo, MI, 1988.
15. **Cohn JN** and Olivari MT. Use of nitrates in congestive heart failure. *Cardiovascular Reviews and Reports* 1984;5:323-327.
16. **Cohn JN**. Vasodilator therapy and angina. *Cardiovascular Reviews and Reports* 1983;4:709-714.
17. Pierpont GL, **Cohn JN**. Comparison of the renal effects of vasodilators used to treat congestive heart failure. *Cardiovascular Reviews and Reports* 1981;2:1199-1209.
18. **Cohn JN**. Choice and rationale for vasodilators in the treatment of hypertension or relief of heart failure. *Cardiovascular Reviews and Reports* 1980;1:696-691.
19. **Cohn JN**. Heart disease in the hypertensive patient. *Med Clin North Am* 1977; 61: 581-591.
20. **Cohn JN**. Hepatocirculatory failure. *Med Clin North Am* 1975;59:955-962.
21. **Cohn JN**. Oral diuretics in hypertension. *Consultant* 1974;133-135.
22. **Cohn JN**. Cardiovascular Drugs - An era of specificity. *Mod Med* 1972;40:14-18.
23. **Cohn JN**. Therapy of shock caused by myocardial infarction. *Heart Bul* 1970;19:49-51.
24. **Cohn JN**. Treatment of shock following myocardial infarction. *J Iowa Med Soc* 1969;758-757; *J Kansas Med Soc* 1969;70:394-398; *Michigan Med* 1969;68:803-805; *California Med* 1969;111:66; *South Dakota J Med* 1969;22:75; *Med Ann DC* 1970; 39:154-159; *Wisconsin Med J* 1970;69:118-120; *Ohio State Med J* 1970;66:137-139.
25. **Cohn JN**. Pharmacologic approach to the low cardiac output of clinical shock. *Proc 3rd Int Pharmacol Meeting* 1968;3:57-64.
26. **Cohn JN**. Treatment of shock. *GP* 1966;34:78-85.
27. **Cohn JN**, Koppanyi T. Human Pharmacology: Part II. Human assay of diuretic agents. *Georgetown Med Bull* 1964;17:152-155.

28. Koppányi T, **Cohn JN**. Human Pharmacology: Part I. A catalyst to clinical research. *Georgetown Med Bull* 1964;17:146-151.

Books & Textbooks

1. Willerson JT, Cohn JN, Editors. *Cardiovascular Medicine*, 2d Ed. Churchill Livingstone, New York. 2000.
2. Patel SS, Cohn JN, Willerson JT, Eds: *Handbook of Cardiovascular Clinical Trials*. Churchill Livingstone Inc., New York, 1997.
3. Willerston JT, Cohn JN, Editors. *Cardiovascular Medicine*. Churchill Livingstone. 1995.
4. Cohn JN, Editor. *Drug Treatment of Heart Failure. Advanced Therapeutics Communications, Inc., New York, NY, Publisher, 1983.*
5. Cohn JN, Editor. *Early Intervention in Acute Myocardial Infarction*. University of Minnesota Press, 1983.

Chapters

1. Florea VG, **Cohn JN**. Disease prevention in heart failure. In: Mann DL, Felker GM, Eds. *Heart Failure: A Companion to Braunwald's Heart Disease 3rd Ed.* Elsevier, Pennsylvania. 2016; pp. 499-513.
2. Francis GS, **Cohn JN**: Cardiac failure and the autonomic nervous system. In: *Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System*. Eds: Mathias CJ, Bannister R. 5th Edition. Oxford University Press, 2013:761-769.
3. Florea VG, **Cohn JN**. Disease prevention in heart failure. In: Mann DL, Ed. *Heart Failure: A Companion to Braunwald's Heart Disease 2nd Ed.* Elsevier Saunders, Missouri. 2011; pp. 610-625.
4. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman DS, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, **Cohn JN**, Faergeman O, Bahr RD, Koenig W, Demirovic J, Arking D, Herrera VLM, Badimon JJ, Goldstein JA, Touchard AG, Rudy Y, Airaksinen KEJ, Schwartz RS, Riley WA, Mendes RA, Douglas PS, Prediman KS. From vulnerable plaque to vulnerable patient – Part III. The SHAPE Paradigm – Screening for Detection and Treatment of Asymptomatic Atherosclerosis, Task Force Report, Executive Summary. In: Naghavi M, Berman D, Falk E, Fayad Z, Nasir K, Budoff M, Hecht H, Shah PK, Eds. *Asymptomatic Atherosclerosis – Pathophysiology, Detection and Treatment*. Springer Science+Business Media, LLC, New York, 2010, pp. 517-535.
5. Duprez DA, **Cohn JN**. Arterial elasticity/stiffness. In: Naghavi M, Berman D, Falk E, Fayad Z, Nasir K, Budoff M, Hecht H, Shah PK, Eds. *Asymptomatic Atherosclerosis – Pathophysiology, Detection and Treatment*. Springer Science+ Business Media, LLC, New York, 2010, pp. 225-235.

6. Givertz MM, **Cohn JN**. Pharmacologic Management of heart failure in the ambulatory setting. In: Antman EM, Givertz MM, Josephson ME, de Lemos J, Oparil S, Sacks FM, Eds. *Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease*, 3rd Ed. Saunders Elsevier, Philadelphia. 2007; pp. 331-355.
7. Duprez DA, **Cohn JN**. Small artery elasticity index, endothelial function and cardiovascular risk. In *Handbook of Hypertension: Arterial Stiffness in Hypertension*, vol. 23:16. Edited by Safar ME, O'Rourke MF. Amsterdam:Elsevier; 2006;257-265.
8. **Cohn JN**, Duprez D. Early detection of vascular disease as a strategy to prevent morbid events. In: *Cornary Artery Disease: Risk Promoters, Pathophysiology and Prevention*, Rao GHR, Thanikachalam S, eds. Jaypee Brothers, New Delhi. 2005, pp. 125-132.
9. Ooi H, **Cohn JN**. Prognostic indicators and assessment of therapeutic responses. In: WS Colucci, Ed. *Atlas of Heart Failure: Cardiac Function and Dysfunction*, 3d Ed. Current Medicine, Inc., Philadelphia. 2002;pp. 145-159.
10. Givertz MM, **Cohn JN**. Ambulatory management of heart failure. In: *Cardiovascular Therapeutics*. Colucci WS, Gotto AM, Josephson ME, Loscalzo J, Oparil S, Popma JJ, Eds. WB Saunders Company, New York, 2002, pp. 325-355.
11. **Cohn JN**. Angiotensin-converting enzyme (ACE) inhibitors in heart failure. In: *Angiotensin-Converting Enzyme (ACE):Clinical and Experimental Insights*. TD Giles, Ed. Health Care Communications, Fort Lee, NJ, 2001:213-17.
12. Loeb HS, **Cohn JN**. Shock. In: *Cardiovascular Medicine*, 2d Ed., Willerson JT, Cohn JN, Eds. Churchill Livingstone, New York. 2000;1529-36.
13. Waeber B, Brunner HR, Burnier M, **Cohn JN**. Hypertension. In: *Cardiovascular Medicine*, 2d Ed., Willerson JT, Cohn JN, Eds. Churchill Livingstone, New York. 2000;1496-1528.
14. McVeigh GE, Bank AJ, **Cohn JN**. Arterial compliance. In: *Cardiovascular Medicine*, 2d Ed., Willerson JT, Cohn JN, Eds. Churchill Livingstone, New York. 2000;1479-95.
15. **Cohn JN**. The management of heart failure. In: *Cardiovascular Medicine*, 2d Ed., Willerson JT, Cohn JN, Eds. Churchill Livingstone, New York. 2000;1165-83.
16. **Cohn JN**. Pathophysiology and clinical recognition of heart failure. In: *Cardiovascular Medicine*, 2d Ed., Willerson JT, Cohn JN, Eds. Churchill Livingstone, New York. 2000;1147-64.
17. **Cohn JN**. Commentary. Clinical trials of ACE inhibitors: pathogenetic insights and therapeutic advances. Husain A, Graham R, eds., *Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery*. Harwood Academic Publishers, Amsterdam. 2000:201-203.

18. Francis GS, **Cohn JN**. Cardiac failure and the autonomic nervous system. In: *Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System*. Eds: Bannister R, Mathias CJ. 4th Edition. Oxford University Press, 1999:477-486.
19. **Cohn JN**. Angiotensin-converting enzyme inhibitors in heart failure. In: *100 Years of the Renin-Angiotensin System*. Eds: MG Nicholls, HR Brunner, H Ikram, CS Sweet, JF Walker. Hughes Associates, Oxford, U.K. 1998:149-151.
20. **Cohn JN**. Management of hypertensive patients with dilated cardiomyopathy (systolic dysfunction). In: *Hypertension Primer (2d Ed)*. Eds: JL Izzo, HR Black. American Heart Association, Dallas. 1999: 405-406.
21. Osayamen MO, Rector TS, **Cohn JN**. Prognosis, use of prognostic variables, and assessment of therapeutic responses. In: *WS Colucci, Ed. Atlas of Heart Failure: Cardiac Function and Dysfunction, 2d Ed*. Current Medicine, Inc., Philadelphia. 1999:8.1-13.
22. **Cohn JN**. Medical treatment of heart failure: problems in dilated cardiomyopathy. In: *Advances in Cardiomyopathies*. Eds: F Camerini, A Gavazzi, R De Maria. Springer-Verlag Italia, Milano. 1998:229-235.
23. **Cohn JN**. Rationale for angiotensin receptor blockade in the therapy of heart failure. In: *Potential benefits of angiotensin-II receptor antagonism in the treatment of cardiovascular and renal diseases (Proceedings of international symposium, 18th Congress of the European Society of Cardiology)*. Novartis International Symposium Series 1997;2:25-30.
24. **Cohn JN**. Heart failure: mechanisms and assessment. In: *Handbook of Hypertension, Vol. 18: Assessment of Hypertensive Organ Damage*. Hansson L, Birkenhager WH, eds. Elsevier Science B.V., Amsterdam, 1997, 175-183.
25. McVeigh GE, Finkelstein SM, **Cohn JN**. Pulse contour and impedance parameters derived from arterial wave form analysis. In: *Functional Abnormalities of the Aorta*, Boudoulas H, Toutouzas P, Wooley CF (Eds). Futura Publishing Co., Inc., Armonk, NY. 1996:183-193.
26. **Cohn JN**. Approach to the patient with heart failure. In: *Kelley WN, Ed. Textbook of Internal Medicine, 3rd Ed*. J.B. Lippincott Company, New York. 1997; 322-328.
27. Kubo SH, **Cohn JN**. Chronic treatment of the ambulatory patient with heart failure. In: *Cardiovascular Therapeutics*, Smith TW (Ed). WB Saunders Co., Philadelphia. 1996: 210-230.
28. **Cohn JN**, Ziesche S, Johnson G, Cobb F. Use of exercise gas exchange measurements in multicenter drug studies. In: *Wasserman, K (Ed): Exercise Gas Exchange in Heart Disease*. Futura Publishing Company, Inc., Armonk, NY. 1996, 245-256.
29. Francis GS, McDonald KM, **Cohn JN**. Pharmacological interventions in experimental remodeling: Angiotensin-converting enzyme inhibitors and angiotensin II subtype I receptor blockers. In: *Dhalla NS, Beamish RE, Takeda N, Nagano M, Eds. The Failing Heart*. Lippincott-Raven, New York, 1995:247-252.

30. **Cohn JN**. Prevention and reversal of ventricular remodeling. In: Dhalla NS, Beamish RE, Takeda N, Nagano M, Eds. *The Failing Heart*. Lippincott-Raven, New York, 1995:193-196.
31. **Cohn JN**. Pharmacologic support of the failing circulation in acute myocardial infarction. In: Francis GS, Alpert JS, Eds. *Coronary Care*, 2nd Edition. Little, Brown and Company, New York. 1995:251-260.
32. Rector TS, **Cohn JN**. Prognosis, use of prognostic variables, and assessment of therapeutic responses. In: Braunwald E, Series Ed., *Atlas of Heart Diseases*, and Colucci WS, Volume Ed., Volume IV, *Heart Failure: Cardiac Function and Dysfunction*. Mosby, Philadelphia. 1995; Vol. IV, 8.1-8.10.
33. Waeber B, Brunner HR, Burnier M, **Cohn JN**: Hypertension. In: Willerson JT, Cohn JN, Eds. *Cardiovascular Medicine*. Churchill Livingstone. 1995:1228-1263.
34. McVeigh GE, Bank AJ, **Cohn JN**: Vascular compliance. In: Willerson JT, Cohn JN, Eds. *Cardiovascular Medicine*. Churchill Livingstone. 1995:1212-1227.
35. **Cohn JN**: Heart failure. In: Willerson JT, Cohn JN, Eds. *Cardiovascular Medicine*. Churchill Livingstone. 1995:947-979.
36. Kubo SH, **Cohn JN**. Approach to treatment of the patient with heart failure in 1994. In: Schrier RW, Abboud FM, Baxter JD, Fauci AS, eds. *Advances in Internal Medicine*, Vol. 39. Mosby-Year Book, Inc. 1994:485-515.
37. **Cohn JN**. Methods of evaluation of arterial compliance. In: Izzo JL, Black HR, eds. *Hypertension Primer*, American Heart Association, 1993;252-253.
38. **Cohn JN**. Overview of pathophysiology of clinical heart failure. In: Hosenpud JD, Greenberg BH, eds. *Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management*. Springer-Verlag. 1993:11-16.
39. **Cohn JN**. Principles of vasodilator therapy in congestive heart failure: impact on mortality. Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. *Cardiovascular Pharmacology and Therapeutics*. Churchill Livingstone, Inc. 1993:791-796.
40. **Cohn JN**. Drugs used to control vascular resistance and capacitance. In: Schlant RC, Alexander RW, O'Rourke RA, Roberts R, Sonnenblick EH, eds. *Hurst's The Heart*, 8th Edition. McGraw Hill, Inc. 1993:611-620.
41. **Cohn JN**, Sonnenblick EH. Diagnosis and therapy of heart failure. In: Schlant RC, Alexander RW, O'Rourke RA, Roberts R, Sonnenblick EH, eds. *Hurst's The Heart*, 8th Edition. McGraw Hill, Inc. 1993:557-571.

42. Rector TS, **Cohn JN**. Assessment of therapeutic efficacy in patients with chronic heart failure. In: Barnett DB, Pouleur H, Francis GS, eds. *Congestive Cardiac Failure: Physiology and Treatment*. Marcel Dekker, Inc. 1993;93-101.
43. **Cohn JN**. How to evaluate the efficacy of vasodilators: effect on exercise tolerance and quality of life. Monograph: *Proceedings of Impact of Recent Therapeutic Advances in the Management of Heart Failure*, November 15, 1992, New Orleans, LA. GEM Communications, Stamford CT. 1993;9-10.
44. Rector TS, **Cohn JN**. Chronic heart failure: Incidence, prognosis and the effects of medical interventions. In: Kapoor AS, Singh BN, eds. *Prognosis and Risk Assessment in Cardiovascular Disease*. Churchill Livingstone Inc. 1993; 283-289.
45. **Cohn JN**. The role of vascular compliance in abnormalities of hypertension and atherosclerosis. Monograph: *Proceedings of Council on Hypertension and Atherosclerosis Education Symposium*, January 1991, La Quinta, CA. AudioVisual Medical Marketing, Inc., New York, 1992;55-60.
46. Francis GS, **Cohn JN**. Cardiac Failure and the autonomic nervous system. In: Bannister R and Mathias CJ, eds. *Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System*, 3rd edition. Oxford University Press 1992; 822-838.
47. **Cohn JN**. Congestive Heart Failure. In: Rakel RE, ed. *Conn's Current Therapy*. W.B. Saunders Company, 1992;243-246.
48. **Cohn JN**. Cardiac consequences of vasomotor changes in the periphery: Impedance and preload. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. *The Heart and Cardiovascular System*, 2nd Ed. Raven Press, 1991; 1369-1378.
49. **Cohn JN**. Clinical heart failure: Future directions. In: Zipes DP, Rowlands DJ, eds. *Progress in Cardiology*. Lea & Febiger, 1991;79-87.
50. **Cohn JN**. Approach to the patient with cardiac failure. In: Kelley WN, et al, eds. *Internal Medicine*. J.B. Lippincott Company, 1991;340-347.
51. Olivari MT, **Cohn JN**. Strategies for therapy of early and advanced heart failure. In: Kapoor AS, Laks H, Schroeder JS, Yacoub MH, eds. *Cardiomyopathies and Heart-Lung Transplantation*. McGraw-Hill, Inc., 1991;37-46.
52. **Cohn JN**, Finkelstein S, Kubo S, McVeigh G, McDonald K, Burns D, Carlyle P:. Vascular compliance in heart failure, a contributor to impedance and the response to vasodilator drugs. In: Lewis BS, Kimchi A, eds. *Heart Failure Mechanisms and Management*. Springer-Verlag, 1991;42-44.
53. **Cohn JN**. What vascular effects should be measured in antihypertensive drug research? In: Morganrath J, Moore EN, eds. *Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia*.

- (Proceedings of 10th Annual Symposium on New Drugs & Devices) Kluwer Academic Publishers, 1990, 25-34.
54. **Cohn JN**. Vasodilator therapy for cardiomyopathy. In: Baroldi G, Camerini F, Goodwin JF, eds. *Advances in Cardiomyopathies*. Springer-Verlag, 1990; 428-434.
 55. **Cohn JN**. Pharmacologic support of the failing circulation in acute myocardial infarction. In: Francis GS, Alpert J, ed. *Modern Coronary Care*. Little, Brown and Company, Boston/Toronto/London, 1989; 14: 255-265.
 56. **Cohn JN**. Drugs used to control vascular resistance and capacitance. In: Hurst JW, ed. *The Heart*. McGraw-Hill, New York, 1989, 94: 1673-1682.
 57. **Cohn JN**. Vasodilator therapy of heart failure. In: Dollery CT, Sherwood LM, ed. *Cardiac and Renal Failure: An expanding role for ACE inhibitors*. Hanley and Belfus, Inc., Philadelphia, 1989; 185-194.
 58. **Cohn JN**. Approach to the patient with heart failure. In: Kelley WM, ed. *Textbook of Internal Medicine*. J.B. Lippincott Company, 1988, pp. 380-386.
 59. **Cohn JN** and Veterans Administration Cooperative Study Group. Treatment of congestive heart failure in acute myocardial infarction. In: Higgins MW, Luepker RV, ed. *Trends in Coronary Disease Mortality. The Influence of Medical Care*. Oxford University Press, 1988, pp. 185-189.
 60. Wilson BC, **Cohn JN**. Right ventricular infarction: Clinical and pathophysiologic considerations. In: Stollerman GH, ed. *Advances in Internal Medicine*. Year Book Medical Publishers 1988; 33: 295-310.
 61. **Cohn JN**. Status of vasodilators for heart failure. In: Morganroth J, Moore E. Neil. *Congestive Heart Failure*. Martinus Nijhoff Publishing, 1987, pp. 187-192.
 62. Carson P, Carlyle P, **Cohn JN**. Hemodynamic, neurohumoral, and renal response to atrial natriuretic peptide infusion in the conscious dog. In: Brenner. *Biologically Active Atrial Peptides*. Raven Press, 1987, pp. 322-325.
 63. **Cohn JN**. Cardiac consequences of vasomotor changes in the periphery: Impedance and preload. In: Fozzard H.A. *The Heart and Cardiovascular System*. Raven Press, 1986, pp. 1525-1533.
 64. **Cohn JN**. The Advisory Committees, Industry, and the Food and Drug Administration. In: Scriabine A, ed. *New Cardiovascular Drugs*, Raven Press, 1986, pp. 259-263.
 65. **Cohn JN**. Drugs used to control vascular resistance and capacitance. In: Hurst JW, ed. *The Heart*. McGraw-Hill, New York, 1986, pp. 1583-1592.
 66. Francis GS, **Cohn JN**. Afterload reduction. In: Maronde RF. *Topics in Clinical Pharmacology and Therapeutics*. Springer-Verlag, New York, Berlin Heidelberg, Tokyo, 1986, pp. 135-150.

67. **Cohn JN**: Clinical evaluation of cardiovascular drugs. In: McMahon FG, ed. Principles and Management of Congestive Heart Failure: Implications for Clinical Care. Quality of Life and Cardiovascular Care 1985; 1: 262-266. Techniques of Human Research and Therapeutics: Selected Topics. Futura Publishing Company, Inc., 1985, pp. 5-15.
68. Francis GS, **Cohn JN**. Vasoactive drugs and the failing ventricle. In: Levine HJ, Gaasch WH, ed. The Ventricle. Martinus Nijhoff, Boston 1985, pp. 315-336.
69. **Cohn JN**, Rector T. Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs. In: Morganroth J, Moore EN, ed. Cardiac Arrhythmias: New Therapeutic Drugs and Devices, Martinus Nijhoff Publishing 1985, pp. 201-211.
70. **Cohn JN**. Nitrate therapy of congestive heart failure. In: Mononitrates. Cohn JN, Rittinghausen, ed. Springer-Verlag, New York 1985, pp. 299-305.
71. **Cohn JN**. Assessment of vasodilatation in man. 3rd Int. Symp. Mechanisms of Vasodilation. Sydney 1983. Bibliotheca Cardiol No. 38, Karger, Basel 1984, pp. 250-261.
72. **Cohn JN**, Bache RJ, Schwartz JS. Calcium entry blockers in coronary artery disease. In: Rubin RP, Weiss GB, Putney JW, ed. Calcium in Biological Systems, 1985, pp. 471-477.
73. **Cohn JN**. Vasodilators in acute myocardial infarction. In: Morganroth J. and Moore EN, ed. Interventions in the Acute Phase of Myocardial Infarction. Martinus Nijhoff Publishing, 1984, pp. 144-151.
74. Francis GS, **Cohn JN**. Angina pectoris and chronic congestive heart failure: Pathophysiology and therapy. In: Antonaccio M, ed. Cardiovascular Pharmacology. Raven Press, 1984, pp. 295-327.
75. **Cohn JN**. A comprehensive approach to the treatment of heart failure. In: Cohn JN, ed. Drug Treatment of Heart Failure. Advanced Therapeutics Communications, Inc., New York, NY, Publisher, 1983, pp. 199-205.
76. **Cohn JN**. Treatment of heart failure in perspective: An overview. In: Cohn JN, ed. Drug Treatment of Heart Failure. Advanced Therapeutics Communications, Inc., New York, NY, Publisher, 1983, pp. 1-12.
77. **Cohn JN**. Hemodynamic role of vasodilators and calcium entry blockers in hypertension. In: Dollery CT, Frohlich ED, ed. Proceedings of an International Symposium: Mechanisms of action of antihypertensive drugs. J.L. Shapiro Associates Inc., Metuchen, NJ, Publisher, 1983, pp. 79-90.
78. **Cohn JN**. Beneficial effects of captopril therapy for refractory heart failure. In: Gorlin R, Romankiewicz JA, ed. Converting enzyme inhibition in heart failure: Management Strategies of the 80's, 1983, pp. 17-23.

79. **Cohn JN**. Hemodynamic role of vasodilators and calcium entry blockers in hypertension. In: Dollery CT, Frohlich Ed, ed. Proceedings of an international symposium. Mechanisms of Action of Antihypertensive Drugs. Health Communications Inc., Metuchen, New Jersey, 1983; pp. 79-90.
80. **Cohn JN**, Nath KA. What is the stimulus to myocardial hypertrophy? In: Tarazi RC and Dunbar JB, ed. Perspectives in Cardiovascular Research. Raven Press, New York, 1983, pp. 21-26.
81. **Cohn JN**, Levine TB, Pierpont G. Early experience with captopril in congestive heart failure. In: Just H, Bussman W-D, ed. Vasodilators in Chronic Heart Failure. Springer-Verlag, Berlin, Heidelberg, New York, 1983, pp. 147-153.
82. **Cohn JN**. Pharmacologic principles in the use of new inotropic agents. In: Morganroth J, Moore EN, ed. Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment. Martinus Nijhoff Publishers, Boston, 1983, pp. 250-255.
83. **Cohn JN**. Nitroprusside in acute myocardial infarction. In: Cohn JN, ed. Early Interventions in Acute Myocardial Infarction. University of Minnesota Press, 1983, pp. 43-48.
84. **Cohn JN**. Introduction: Prognosis in acute myocardial infarction. In: Cohn JN, ed. Early Intervention in Acute Myocardial Infarction. University of Minnesota Press, 1983, pp. 1-6.
85. **Cohn JN**. The present role of vasodilator therapy in cardiac failure. In: Coltart J, Jewitt DE, ed. Recent developments in cardiovascular drugs. Churchill Livingstone, Edinburgh London Melbourne and New York, 1982, pp. 191-199.
86. **Cohn JN**. Problems in clinical evaluation. In: Braunwald E, Mock MB, Watson J, ed. Congestive Heart Failure. Grune and Stratton Inc., New York 1982, pp. 367-76.
87. **Cohn JN**. Part II: Clinical definitions and studies. In: Braunwald E, Mock MB, Watson J, ed. Congestive Heart Failure. Grune and Stratton Inc., New York, 1982, pp. 11-13.
88. **Cohn JN**. Vasodilators: Rationale, application and future prospects. In: Braunwald E, Mock MB, Watson J, ed. Congestive Heart Failure. Grune and Stratton Inc., New York, 1982, pp. 279-289.
89. **Cohn JN**, Hamosh P. Experimental observations on pulsus paradoxus and hepatojugular reflux. In: Reddy PS, Leon DF, Shaver JA, ed. Pericardial Disease. Raven Press, New York, 1982, pp. 249-258.
90. **Cohn JN**. Importance of alpha blocking and vasodilator effects of beta blocking agents. In: Morganroth J, Moore EN, ed. The Evaluation of Beta Blocker and Calcium Antagonist Drugs. Martinus Nijhoff Publishers, The Hague, The Netherlands, 1982, pp. 63-71.

91. **Cohn JN**. Systemic vascular resistance: Regulation and effect of left ventricular function. In: Case DB, Sonnenblick EH, Laragh JH, ed. Captopril and Hypertension, Plenum Publishing Corporation, New York, 1981, pp. 77-86.
92. **Cohn JN**, Levine TB, Francis GS. Responses of the sympathetic and renin-angiotensin systems in congestive heart failure. In: Goodwin JF, Hjalmarson A, Olsen EGJ, ed. Congestive Cardiomyopathy, AB Hassle, Sweden 1981, pp. 319-322.
93. **Cohn JN**. General principles of treatment with vasodilators. In: Lichtlen PR, Engel HJ, Schrey A, Swan HJC, ed. Nitrates III - Cardiovascular Effects, Springer-Verlag, New York, 1981, pp. 461-468.
94. **Cohn JN**, Franciosa JA, Francis GS. Nitroprusside infusion in acute myocardial infarction. In: Ryden L, Conradson TB, ed. Vasodilators In Congestive Heart Failure, 1981, pp. 125-128.
95. **Cohn JN**. Pathophysiological considerations in selecting vasodilator therapy for congestive heart failure. In: Ryden L, Conradson TB, ed. Vasodilators In Congestive Heart Failure, 1981, pp. 93-98.
96. **Cohn JN**, Franciosa JA. Effect of systemic vasoconstriction on left ventricular function: Implications regarding hypertension and heart failure. In: The Heart In Hypertension. Strauer BE, editor. Springer-Verlag, New York. 1981, pp. 307-311.
97. **Cohn JN**, Franciosa JA. Oral isosorbide dinitrate in the management of chronic left ventricular failure. In: Nitrate II, Rudolph W and Schrey A, eds, Urban and Schwarzenber, Munich, 1980, pp. 217-220.
98. **Cohn JN**. Oral vasodilators should be used routinely in the treatment of congestive heart failure. IN: Rapaport F, ed. Current Controversies in Cardiovascular Disease. W.B. Saunders Co., Philadelphia, 1980, pp. 607-612.
99. **Cohn JN**. Shock. In: Hurst JW, ed. The Heart. New York, McGraw-Hill
100. **Cohn JN**. Treatment of cardiac failure with vasodilators. In: Gross F, ed. Modulation of Sympathetic Tone in the Treatment of Cardiovascular Diseases. Hans Huber Publishers, Bern, 1978, pp. 1982-1991.
101. **Cohn JN**. Unloading the failing heart. In: Fishman, ed. Heart Failure. Hemisphere Publishing Corporation, Washington, D.C. 1978, pp. 301-310.
102. **Cohn JN**. Renal hemodynamic alterations in liver disease. In: Suki WN, ed. The Kidney in Systemic Disease, New York, John Wiley and Sons Inc, 1976, pp. 225-234.
103. **Cohn JN**. Cardiogenic shock. In: Chung EK ed. Cardiac Emergency Care, Philadelphia, Lea and Febiger, 1975, pp. 35-50.

104. **Cohn JN**. Nitroprusside therapy of heart failure in hypertensive and non-hypertensive vasoconstricted states. In: Milliez P, Safar M, ed. Recent Advances in Hypertension, Monte-Carlo, International Symposium 1975, pp. 269-274.
105. **Cohn JN**. Evaluation of alpha stimulants and blockers. In: McMahon FF, ed. Principles and Techniques of Human Research and Therapeutics, Mount Kisco, Futura Publishing Co, 1974, pp. 209-220.
106. **Cohn JN**, Franciosa JA. Pathophysiology of shock in acute myocardial infarction. In: Yu P, Goodwin J, ed. Progress in Cardiology, Vol 2, Philadelphia, Lea and Febiger, 1973, pp. 207-234.
107. **Cohn JN**, Rodriguera E, Guiha NH. Left ventricular function in hypertensive heart disease. In: Onesti G, Kim K, ed. Hypertension Mechanisms and Management, New York, Grune and Stratton Inc, 1973, pp. 191-197.
108. **Cohn JN**. The patient in shock. In: Lauer DP, ed. Clinician: Managing Medical Emergencies, New York, Medcom, 1972, pp. 103-109.
109. **Cohn JN**. The management of shock in myocardial infarction. In: Harrison DC, ed. Management of Acute Myocardial Infarction, New York, Medcom Medical Update Series, 1972; pp. 75-83.
110. **Cohn JN**. Monitoring the patient in cardiogenic shock. In: Shock in Low- and high flow states: proceedings of a symposium at Brook Lodge. Augusta, Michigan, 1971. Excerpta Medica, Amsterdam, 1972, pp.106-110.
111. **Cohn JN**. Bedside evaluation of left and right ventricular function in myocardial infarction. In: Bartorelli C, Zanchetti A, ed. Cardiovascular Regulation in Health and Disease, Milan, 1971, pp. 239-244.
112. **Cohn JN**. Hemodynamic technics in the study of liver diseases. In: Sunderman FW, Sunderman FW Jr, ed. Laboratory Diagnosis of Liver Diseases. St. Louis, Warren H. Green, Inc., 1968, pp. 388-393.
113. **Cohn JN**. Acute myocardial infarction. In: Conn HF, ed. Current Therapy. Philadelphia, W.B. Saunders. 1967, pp. 173-179.
114. **Cohn JN**. Venous hypotension as related to cardiac output in shock. In: Mills, ed. Shock and Hypotension. New York, Grune and Stratton. 1965, pp. 250-256.

PROFESSIONAL SERVICE AND PUBLIC OUTREACH

Editorships/Journal Reviewer Experience

Editor

Progress in Cardiovascular Diseases

Drug Treatment of Heart Failure (textbook)

Journal of Cardiac Failure (Editor-in-Chief, peer-reviewed, Churchill Livingstone, 1994-2002)

Cardiovascular Medicine (textbook, Churchill Livingstone, 1995, 3rd Edition 2007)

Editorial Positions Held

Editorial Board, *The American Journal of Cardiology*

Editorial Board, *American Journal of Geriatric Cardiology*

Editorial Board, *American Journal of Hypertension*

Editorial Board, *Cardiovascular Drugs and Therapy*

Editorial Board, *Cardiovascular Drug Therapy*

Editorial Board, *Circulation*

Editorial Board, *Circulation: Heart Failure*

Editorial Board, *Current Heart Failure Reports*

Editorial Board, *CVD Prevention, The Journal of the International Society Federation of Cardiology*

Editorial Board, *Indian Heart Journal*

Editorial Board, *Italian Heart Journal*

Editorial Board, *Heart Failure*

Editorial Board, *High Blood Pressure and Cardiovascular Prevention*

Editorial Board, *Hypertension*

Editorial Board, *Journal of the American College of Cardiology*

Editorial Board, *Journal of Cardiovascular Pharmacology*

Editorial Board, *Journal of Cardiovascular Pharmacology and Therapeutics*

Editorial Board, *Journal of Cardiovascular Risk*

Editorial Board, *Journal of Clinical Research and Drug Development*

Editorial Board, *Journal of Geriatric Cardiology*

Editorial Board, *Journal of Medicine*

Editorial Board, *Postgraduate Medicine*

Editorial Board, *The Journal of Hypertension*

Editorial Board, *The Journal of Laboratory and Clinical Medicine*

Guest Editor, *Circulation*, 2005

Guest Editor, New Therapeutic Strategies for Heart Failure: Potential Impact of Cardiac Support Devices on Ventricular Remodeling, *Journal of Cardiac Failure*, Vol. 10, No. 6, Supplement Issue, 2004

Guest Editor, Update on Cardiovascular Disease: Recent Findings and Newest Therapeutic Choices, Role of AT₁ Receptors in Target Organ Disease: A Functional Perspective, *American Journal of Hypertension*, Vol 13, Supplement Issue, 2000

Guest Co-Editor, Consensus Recommendations for the Management of Chronic Heart Failure, *The American Journal of Cardiology*, Vol 83, Supplement 2A, 1999

Guest Editor, The Therapeutic Role of Calcium Antagonists: Current Evidence and Future Proposals, *Journal of Hypertension*, Vol. 14 Supplement 4, 1996

Guest Editor, From Hypertension to Heart Failure: Endothelial Dysfunction and Structural Changes in Cardiovascular Disease, *The American Journal of Cardiology*, Vol. 76, No. 15, 1995

Guest Editor, Sympathetic Nervous System and Heart Failure, *Clinical Cardiology*, Volume 18 Supplement I, 1995

Guest Editor, New Insights in the Management of Congestive Heart Failure, *Drugs*, Volume 47 Supplement 4, 1994

Guest Editor, The Vasodilator-Heart Failure Trials (V-HeFT): Mechanistic Data from the VA Cooperative Studies, *Circulation*, Supplement VI, June 1993

Guest Editor, A Symposium: Angiotensin-Converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure, *The American Journal of Cardiology*, October 2, 1990

Guest Editor, The Role of the Adrenergic System in Heart Failure, *European Heart Journal*, April 1990

Guest Editor, Symposium on Bepridil: A New Antianginal Agent, *The American Journal of Cardiology*, March 15, 1985

Guest Editor, New Concepts in the Mechanisms and Treatment of Congestive Heart Failure, *The American Journal of Cardiology*, January 11, 1985

Guest Editor, Hypertension, Renal Hormonal and Neural Mechanisms, *Circulation Research*, July 1978

Guest Editor, Hypertension: Experimental and Clinical Studies, *Circulation Research*, May, 1977